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ABSTRACT 
T lymphopoiesis has been an intense focus of immunological research since the 
discovery of the major histocompatibility complex (MHC) and T cell mediated transplant 
rejection. Additionally, researchers have long appreciated the role ofT cells, and their 
development, in autoimmune disorders. Interest in this field has increased upon the 
realization that many leukemic oncoproteins are the very factors that control normal T 
cell development. Thus, the transcriptional networks that drive the function and 
development of T lymphocytes are closely linked with disease states. 
Growth Factor Independence 1 (GFII) and GFIlB are two very similar 
transcriptional repressor oncoproteins that are encoded by two different genes. Though 
nearly identical in their DNA binding and repressor domains, GFIl and GFIlB are 
differentially expressed in normal tissues and in tumors of lymphoid lineage. GFIl is 
frequently activated in mouse T cell leukemias, whereas GFIlB has not been found in T 
cell tumors. The work described in this dissertation provides insight into this 
phenomenon by delineating functional differences for GFIl and GFIlB in T cells. 
The first set of experiments compares the phenotypes engendered by transgenic 
expression of either GFIl or GFIlB in developing and mature T lymphocytes. These 
analyses revealed that GFIl enhances the response to T cell activation, whereas GFIlB 
decreases this response. Furthennore, transgenic GFIl B causes defects in thymocyte 
v 
development, some of which result from a lack of survival signals. These defects can be 
corrected by transgenic expression of either BCL2, an inhibitor of apoptosis, or GFIl, 
suggesting that GFIl and GFIlB play opposing roles in T cell survival. 
At least part of1he effect of transgenic GFIlB results from GFIlB-mediated 
repression of Gfil transcription. We show that the transcription of Gfil is repressed in T 
cells by both GFIl and GFIlB and that this is the result of direct binding to evolutionarily 
conserved GFIl/GFIlB recognition sequences in the Gfil promoter. Furthermore, we 
provide evidence that endogenous GFIl regulates its own promoter in T cells, but not in a 
myeloid lineage cell line. 
Finally, a more detailed analysis of the effect ofGFIlB in T lymphopoiesis 
confirms a role for GFHB in the survival and differentiation ofthymocytes. This 
analysis revealed that transgenic expression ofGFIlB results in altered expression of 
several members of T cell receptor (TCR) signaling pathways that are largely responsible 
for the survival and differentiation ofthymocytes. The activity of the downstream 
effectors of these pathways appears to be decreased, providing mechanistic insight in to 
the function of GFIlB in T cells. 
Our work is the first to describe a role for GFIB in T cells. We demonstrate that 
GFIlB negatively regulates the cellular response to activation through the TCR complex 
and provide preliminary evidence of a mechanism by which GFIIB mediates these 
effects. Furthermore, wle delineate functional differences for GFIl and GFIlB in T cells, 
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CHAPTER I 
INTRODUCTION, BACKGROUND, AND RESEARCH OBJECTIVES 
Hematopoiesis, the immune system, and T cell develo.,ment. 
Hematopoiesis-the process by which new blood cells are generated from self-
renewing pluripotent stem cells residing in the bone marrow--consists of two major 
arms, myelopoiesis and lymphopoiesis. Cells that are generated in the myelopoietic 
process include erythrocytes, which carry oxygen and carbon dioxide through the blood 
stream, and megakaryocytes, which generate platelets, cells that are necessary for blood 
clotting at the sites of injury. The remaining myeloid cells, along with all the cells of 
lymphoid lineage, make up the immune system. Immune cells protect the body from 
invasion and disease. 
There are two basic classes of immune response-innate immunity and adaptive 
immunity-and each component of the immune system contributes to one or the other. 
Innate immunity is the body's first response, occurring within hours of invasion. This 
response is not pathogen-specific, and is carried out by several types of cells as well as 
complement factors. Epithelial cells function in innate immunity by forming physical 
barriers against pathogens. Phagocytes (a class of myeloid cells consisting of 
macrophages and neutrophils) act in the innate immune response by engulfing and 
destroying invading pathogens. The lymphoid cells that participate in innate immunity 
are natural killer (NK) cells. NK cells are programmed to destroy any non-self cell with 
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which they come into contact. NK cells discriminate between self and non-self cells by 
recognition of self-MHC Class I on the surface of other cells. (Major Histocompatibility 
Complex, MHC, is discussed in more detail below.) This recognition signals the NK cell 
to suppress the killing machinery, thereby preventing the destruction of self cells. 
The second line of defense, adaptive immunity, occurs over a period of days, and 
is pathogen-specific. In this process, the immune system recognizes and adapts to the 
presence of invading pathogens, resulting in the specific elimination of either invading 
organisms or of infected host cells. Furthermore, the adaptive immune system has 
memory. That is, after the initial infection by an invading organism has been cleared by 
the adaptive immune system, re-introduction of the same pathogen results in a more rapid 
and efficient response. Adaptive immunity comes in two forms, humoral immunity and 
cell-mediated immunity, which are executed by Band T lymphocytes, respectively. B 
cells mediate humoral immunity by secreting antibodies that recognize and bind to 
pathogens, resulting in the destruction of the invader by phagocytes. 
Cell-mediated immunity is controlled by T cells, which become activated against 
pathogens by interaction of the membrane-bound T cell receptor (TCR) complex and 
pathogenic antigens presented on the surface of other host cells in the context of self 
major histocompatibility complex (MHC) molecules. MHC molecules are present on the 
surface of all cells within the body and, under normal physiological conditions, present 
self-antigens to TCRs on mature T cells. This constant low-level interaction contributes 
to the maintenance and survival of a diverse T cell population, a process known as T cell 
homeostasis. However, upon cellular infection or phagocytosis of an invading organism, 
pathogen-specific proteins are processed to produce peptide antigens, which are bound by 
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MHC and presented on the cell's surface. It is this antigenIMHC complex that is 
recognized by the pathogen-specific TCR on circulating T cells, initiating and sustaining 
a cellular immune response. (See Figure 1.) 
There are two types of T lymphocytes, helper T cells and cytotoxic T cells. T 
helper cells are activated by antigen in the context of MHC Class II, which is expressed 
almost exclusively by professional antigen presenting cells. Once activated, a T helper 
cell proliferates (a process known as clonal expansion), promotes the proliferation ofB 
cells, activates macrophages, and promotes inflammation, all of which can contribute to 
the destruction of the invader. Cytolytic T cells are activated by antigen in the context of 
MHC Class I molecules on the surface of infected cells, resulting in the specific lysis of 
the infected target cell by the T cell. All cells express MHC Class I, because any cell in 
the body is a potential target for infection. 
All T cells can be experimentally identified by surface expression of the T cell 
receptor (TCR) complex. Furthermore, T helper cells are easily identified by the surface 
expression of the CD4 co-receptor molecule, and cytotoxic T cells are characterized by 
the expression of the CD8 co-receptor. The TCR complex is responsible for antigen 
recognition and initiation of intracellular activation signals, the latter being largely 
regulated through a family of surface proteins known as the CD3 complex. Both CD4 
and CD8 co-receptors assist in the initiation of signaling cascades, and no qualitative 
difference between the signaling events mediated by the two co-receptors has been 
defined, leaving a mystery as to the mechanisms governing, and the reasons for, the 
specificity of expression of these two co-receptors on the two classes of T cells. 
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Figure 1. T Cell Receptor (TCR)-Major Histocompatibility Complex (MHC) 
interaction. Schematic representation of a TCR recognizing and binding to peptide 
presented by MHC. C~ and V~, respectively, are the constant and variable regions of the 
TCR ~ chain. The peptide antigen is bound in the groove between the a and ~ chains of 







Antigen specificity and affinity of the TCR complex are dictated by the sequences 
of the TCR a and p chains. Diverse sequences are generated by chromosomal 
rearrangement of the variable regions of these genes, which is mediated by the products 
of Recombinase Activating Genes (RAG) 1 and 2, and cannot occur in the absence of 
either RAG 1 or RAG2. Furthermore, surface expression of one successfully rearranged 
TCR a or p chain results in signaling that suppresses further rearrangement on the other 
allele, a process known as allelic exclusion. Allelic exclusion results in the expression of 
only one TCR on most T cells, ensuring that each cell has specific affinity for antigen and 
MHC, providing the required diversity of the cellular immune system. In addition to 
controlling the function of mature T cells in immune responses, the affinity/avidity of 
TCRlMHC interactions also determine the fate of developing T cells in the thymus, a 
process known as T lymphopoiesis (recently reviewed in (1 ;2)). 
T lymphopoiesis begins when T cell precursors, prior to committing to the T 
lineage, leave the bone marrow and enter the thymus. The development of thymocytes is 
tracked and partially defined by the cell-surface expression of the CD4 and CD8 co-
receptors (see Figure 2). The earliest thymocytes express neither CD4 nor CD8 and are 
referred to as double negative (DN) cells. After commitment to the T lineage, DN 
thymocytes express a pre-TCR, which is a heterodimer consisting of the pre-Ta and a 
rearranged TCRP chain. Signals from the pre-TCR are required for further development 
and differentiation into the next stage ofT lymphopoiesis, the double positive (DP) stage, 
where both CD4 and CD8 are expressed on the cell surface. Rearrangement of the TCRa 
chain occurs upon differentiation into the DP stage. Once expressed, the TCRa chain 
replaces pre-Ta and provides the final requirement for a mature TCR complex, signals 
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Figure 2. The stages of T lymphopoiesis. A. Schematic representation of the T 
lymphopoietic process. The most primitive thymocytes express neither CD4 nor CD8 
(double negative, DN). This stage can be further sub-classified based on the expression 
of surface markers CD44 and CD25. Survival and differentiation during the DN stages 
are dependent upon signals from cytokines, such as IL-7, and from the pre-TCR. In the 
next stage of differentiation, cells express both CD4 and CD8 simultaneously (double 
positive, DP), and the TCR replaces the pre-TCR. These early stages ofT lymphopoiesis 
occur in the cortex of the thymus. Finally, thymocytes down-regulate either CD4 or CD8 
to become CD4+ or CD8+ single positive (SP), translocate into the medulla and undergo 
final maturation. This lineage commitment depends on signals from the TCR. B. Flow 
cytometric analysis of CD4 and CD8 expression on C571B16 mouse thymocytes. The 














from which are necessary for further development. The final stage of thymocyte 
maturation requires down-regulation of one or the other co-receptors and results in 
differentiation into either CD4 (helper) or CD8 (cytolytic) single positive (SP) T cells. 
This stage of maturation requires the integration of two distinct processes-positive 
selection, a process by which a cell receives survival signals; and lineage commitment, a 
process by which a cell makes fate decisions that result in the expression of a single co-
receptor. Neither process has been fully defined, though extensive research is ongoing in 
both areas. However, positive selection is absolutely dependent upon appropriate TCR-
mediated signals. In the thymus, as in peripheral T cell homeostasis, TCR signaling 
events are initiated by interaction of the TCR with self-peptide presented by MHC on the 
surface of thymic antigen presenting cells. It is the affinity of this interaction that 
determines whether the maturing T cell survives or dies. 
Signals from both cytokine receptors and the TCR are required for survival and 
positive selection. Death of developing thymocytes occurs as a result of either very weak 
or very strong TCR signals. An insufficient signal results in apoptotic death that is 
referred to as "death by neglect", while a very strong signal results in apoptotic death that 
is known as negative selection. Death by neglect assures that incompetent T cells are not 
released into the immune system, while negative selection assures that autoreactive T 
cells do not escape into the periphery and is vital to the prevention of autoimmune 
disease. 
Survival of developing T cells is dependent upon an intermediate strength of 
signal from the TCR. A thymocyte, in the course of development and migration through 
the thymus, has contact with many different antigen presenting cells (APCs), each 
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presenting self-peptidelMHC complexes for interaction with the TCR. Furthermore, 
cytokines, expressed at different anatomical locations within the thymus, interact with 
their corresponding receptors on the surface of developing thymocytes to provide 
survival signals. For example, deletion ofIL7Ra results in drastically reduced thymic 
cellularity resulting from a severe block to development at the DN stage (3). Thus, a 
combination of TCR signaling and cytokine signaling is critical for T lymphopoiesis. 
Lineage commitment is closely linked to the MHC-specificity of the TCR; 
typically, CD4 SP T cells are restricted on MHC Class II molecules, while CD8 SP T 
cells are restricted on MHC Class I molecules. Furthermore, the MCH loci are comprised 
of several different genes that are highly polymorphic, and it is these polymorphisms that 
form the basis of self and non-self specificity of recognition by T cells. In humans and 
outbred animals, the two different alleles ofMHC genes, both of which are expressed, 
encode distinct polymorphic proteins, resulting in even greater diversity. Each allele is 
designated as a specific haplotype, since it comprises only half of the genetic and 
proteomic information. On the other hand, in inbred laboratory mouse strains, both 
alleles of the MHC locus encode the same polymorphisms, resulting in the expression of 
only one protein for each MHC gene. Therefore, every gene in the MHC locus of these 
mice has the same haplotype designation, which is a small letter of the alphabet (some 
common haplotypes are b, d, and k). Many T cells from a mouse with a particular 
haplotype, by virtue of TCR-MHC interaction, recognize as foreign MHC molecules of 
any other haplotype. This recognition forms the basis for transplant rejection and, 
indeed, was the early discovery that led to the intense interest that has developed in the 
area of T lymphopoiesis. 
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While much is understood about phenotypic and cell-surface changes that 
accompany T lymphopoiesis, and quite a bit has been discovered about early signaling 
events in TCR-mediated activation, a minimal understanding exists of the transcriptional 
network that links the early signaling events to the phenotypic changes. Several 
transcription factors have been implicated in the differentiation of thymocytes, including 
EGR-I, Notchl (a cell-surface receptor that is cleaved upon ligand binding to form 
intracellular Notch (lCN), a transcriptional regulator), and the E2A gene products, El2 
and E47 (4-6). Additionally, the activity of certain transcription factors has been shown 
to increase upon TCR activation, including that ofNF AT, NFKB, and AP-l, each under 
the control of distinct second messengers and/or signaling pathways (recently reviewed in 
(7)). Furthermore, different arms of the mitogen activated protein kinase (MAPK) 
pathway have been shown to preferentially activate during either positive or negative 
selection, providing some insight into how the activation of the same TCR can lead to 
dichotomous outcomes (recently reviewed in (1)). However, an understanding of the 
integration of activation, survival and differentiation signals, which is the key to 
understanding the continuous process of T lymphopoiesis, has remained elusive. 
Gftl and GftlB. 
The Growth Factor Independence-l (GFIl) and GFIlB proteins are closely 
related nuclear oncoproteins that may regulate cytokine pathways. Gfil was originally 
identified as the gene upregulated by insertion of Moloney murine leukemia virus 
(MoML V) in a thymic lymphoma that was selected for its ability to grow in the absence 
of the T-cell cytokine IL-2 (8). GFIl is mildly anti-apoptotic and inhibits growth arrest 
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ofIL-2 dependent T cell lines under conditions of limiting IL-2 (8;9). Furthermore, 
forced expression of Gftl potentiates the outgrowth of cell lines that do not depend on the 
addition ofIL-2 to the media, without inducing production ofIL-2 within the culture (8). 
In fact, 2780a cells that were infected with Gftl-encoding retrovirus escaped both 
apoptosis and Gl arrest induced by the withdrawal ofIL-2 (9). GftlB was identified by 
low stringency hybridization screening with a eDNA probe encoding the zinc-finger 
region of Gftl (10). GFIlB inhibits both growth arrest and IL-6-induced differentiation 
ofMl myelomonocytic cells (10). 
GFIl and GFIlB are 97% homologous in the carboxy-terminal 165 amino acids 
that encode six Cys-His zinc fingers. An amino-terminal20-amino-acid SNAG domain 
(found in the Snail and GFIl family of proteins), which is responsible for nuclear 
localization and transcriptional repressor function, is also highly conserved (9; 1 0) (see 
Figure 3). In fact, a single mutation in the SNAG domain of the Proline at position 2 to 
Alanine (P2A) is sufficient to abrogate repression activity in transient transcription 
assays, without affecting either nuclear localization or DNA binding capability (9). 
Additionally, 2780a cells infected with P2A-GFIl-encoding retrovirus were unable to 
escape Gl arrest in the absence ofIL-2, suggesting that the oncogenic function ofGFIl is 
dependent upon its transcriptional repressor activity (9). 
Consensus DNA recognition sequences for GFIl and GFIlB have been defined 
using bacterially synthesized proteins encoding GST fused to GFIl or GFIlB. Under the 
conditions used to define these sites, GFIl and GFIlB bind to virtually identical DNA 
consensus sequences, defined as 5'-TAAATCAC(A/T)GCA-3' for GFIl and 
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Figure 3. GFIl and GFIlB are similar transcriptional repressors. Gfil and Gfil B 
are 97% homologous in the region encoding the Zn fingers and the proteins recognize the 
same core DNA sequence. The 20-amino-acid SNAG domain ofGFIlB differs from that 





















5'-TAAATCACTGC(Aff)-3' for GFIlB (10;15). The AATC core was observed in 
100% of the sequences that were bound by either GFIl or GFIlB zinc fingers. 
Several GFIl targets genes have been suggested by virtue of being up-regulated in 
Gjirl- mice. These include 1NFR-associated factor (TRAP) 5, Lung Kruppel Like 
Factor (LKLF), and Idl and Id2, all of which have been shown to play roles in T 
lymphopoiesis (11). Additional potential targets for GFIl repression include CIEBPa 
and PU.l, both of which are required for proper development ofneutrophils (16). Other 
putative targets have been identified by chromatin immunoprecipitation (ChIP) analysis, 
and include E2F family members E2F5 and E2F6, and Ets family members Ets2 and 
cMyc. Furthermore, this analysis identified binding by GFIl to the Gjil B promoter in 
three different cell lines (13). Suggested targets for GFIlB have also been identified and 
include suppressor of cytokine signaling (SOCS) 1 and 3 (14) and p21 (10). 
Despite the extensive similarities ofGFIl and GFIlB, each contains a region 
unique in amino acid sequence between the SNAG domain and the Zn fingers, the 
activities of which are yet to be defined. These unique regions may be the key to the 
distinct physiological roles of these two very similar transcription factors. 
Gene deletion studies have shown that Gjil and Gjil B play distinct, pivotal roles 
in hematopoiesis. Gjil-deficient mice display both thymic and peripheral T 
lymphopenia, with severe abnormalities m pre-T cell development (11; 16; 17). 
Furthermore, they display a profound defect in neutrophil differentiation, which leads to 
neutropenia (16;17). In support of this apparent role in neutrophil differentiation, several 
putative targets ofGFIl have been identified, including ELA2, Azu, AAT, and ACT, all of 
which are granulocyte specific genes (13). Additionally, humans have been identified 
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that harbor a single allelic mutation of Gjil, presumably resulting in the expression of a 
dominant negative protein along with the wild type GFIl (Gjildnlwt). These mutations 
were identified in patients with specific types of neutropenia, a phenotype which mimics 
that seen in Gjirl - mice. However, unlike Gjil-deficient mice, which have severe T 
lymphoid abnormalities, the Gjildnlwt patients display only mild disruptions in T cell 
populations. 
While Gjil is essential to proper development of lymphoid and granulocytic cells, 
gene deletion studies in mice revealed that Gjil B is necessary for the development of 
megakaryocytes and for definitive erythropoiesis (18). Deficiency of Gjil B is embryonic 
lethal by day E 15 (18). In accordance with the hematopoietic phenotypes of Gjil and 
Gjil B deficiency, the thymus of adult rats expresses predominantly Gjil, with Gjil B 
being undetectable in Northern analysis of whole thymus. Gjil B is the predominant 
factor expressed in spleen, the major site of erythropoiesis in adults. Both factors are 
expressed in bone marrow, where many types of hematopoietic cells reside, including 
hematopoietic stem cells (10). 
Specific background and research objectives. 
It has been reported that in T cells, transgenic expression of GFIl causes an 
increase in the response to TCR-stimulated activation (19-21). In addition, Gjil 
transcription is upregulated upon TCR-mediated activation of mature T cells (8;21). 
Despite the fact that T lymphopoiesis is driven largely by TCR signals, and that other 
genes that are downstream of TCR-mediated activation, such as EGR-l, have been shown 
to be instrumental in the development ofT cells (4), the expression pattern and role of 
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GFIl in developing thymocytes have not ~en examined. Furthermore, the degree of 
sequence homology between GFIl and GFIlB, along with the similar biochemical and 
oncogenic functions of these two factors, suggest the possibility that GFIlB, if expressed 
in T cells, may perform functions similar to those of GFIl ~ 
To further examine the function ofGFIl in T cells and developing thymocytes, 
and to begin to determine whether GFIlB functions in a similar manner, transgenic mice 
were created that express either GFIl or GFIlB in developing thymocytes and in mature 
T cells. Examination of these GFIl- and GFIlB-transgenic mice in this laboratory 
confirmed that, as previously published, forced expression of GFIl potentiates T cell 
activation in vitro. However, GFIlB-transgenic cells responded poorly to TCR 
activation, a result directly opposite to that observed in GFIl-transgenic cells. 
Furthermore, though expression of transgenic GIF 1 produces no gross thymic phenotype, 
expression of transgenic GFIlB results in anomalies in T cell development. Specifically, 
GFIlB-transgenic mice produce large numbers of CD4 SP thymocytes with phenotypic 
features of maturity, and very few CD8 SP thymocytes. 
My goals for this project were three-fold. First, I sought to determine the 
physiological relevance of the observed effects ofGFIIB on TCR activation in T 
lymphopoiesis by examining expression of endogenous GFIlB in developing 
thymocytes. Though Gfil B could not be detected by Northern analysis of whole rat 
thymus, the possibility remained that this· factor is expressed in certain subsets of 
thymocytes. For example, the DN cells, of which there are four distinct subpopulations, 
make up only about 1-3% of total thymocytes. Therefore, ifGFIlB were expressed in 
only a subset of DN thymocytes, it would be virtually impossible to detect it by 
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previously utilized methods. However, developmental-specific expression of a factor that 
negatively regulates TCR signaling could be instrumental in controlling the survival and 
differentiation of cells. Secondly, I sought to determine the specific T lymphopoietic 
process(es) that may be affected in GFIlB-transgenic mice. Because selection of 
thymocytes is central to their development, I focused on determining whether GFIIB-
transgenic thymocytes are defective in positive selection, negative selection, or both. 
Finally, I wanted to identify downstream targets of GFIl and GFIlB that may mediate 
the observed effects on activation. Several downstream effectors of TCR stimulation are 
well defined, and the interruption or propagation of any of these pathways could result in 
the observed effects on activation. I therefore sought to determine whether GFIlB 
transgenic thymocytes display altered expression levels of members of these signaling 
pathways. 
My second project arose as a result of an observation made regarding the GFIl-
and GFIlB-transgenic mice. Upon Northern analysis of RNA from transgenic 
thymocytes, it was observed that in both GFIl- and GFIlB-transgenic animals there was 
a reduction in endogenous Gfil message. This presented the possibility that GFIl and 
GFIl B may negatively regulate the expression of Gfil. My goals in this project were to 
determine whether the observed repression is direct and whether it is conserved among 
species and cell types. 
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CHAPTER II 
INTRANUCLEAR STAINING OF PROTEINS IN HETEROGENEOUS CELL 
POPULATIONS AND VERIFICATION OF NUCLEAR LOCALIZATION BY 
FLOW CYTOMETRIC ANALYSIS 
Introduction. 
Traditionally, cells and tissues have been tested for the presence of specific 
proteins by biochemical methods such as Western blotting. While this method has 
advantages, such as the determination of apparent molecular weight and oligomerization 
status, it is rather time-consuming. Furthermore, if a protein is expressed at very low 
levels, or in only a fraction of cells in a heterogeneous cell population, Western blotting 
can be unreliable, providing false negative results. For example, Western blot analysis 
failed to detect the transcription factor Growth Factor Independence-IB (GFIlB) in wild 
type thymocytes, even though its expression can be confirmed by R T -peR. It is often 
possible to detect nuclear transcription factors by immunofluorescence microscopy, 
advantages of which include visual interpretation of data in intact cells, allowing the 
determination of not only nuclear vs. cytoplasmic localization, but of subnuclear 
localization patterns as well. However, it is difficult to detect poorly expressed proteins 
with low affinity antibodies by this method, due in part to limitations of the human eye. 
While it is possible to enhance the signal using sophisticated software packages, this 
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requires a skilled and knowledgeable microscopist. We therefore turned to flow 
cytometry to detect GFIlB in thymocyte subsets. 
Flow cytometry is a method whereby the expression of specific molecules can be 
assessed on the single-cell level by using antibodies against the proteins of interest. The 
protein-specific antibodies are conjugated to fluorochromes, and as the cells pass through 
the cytometer, they are exposed to different wavelengths of light to excite the 
fluorochromes, which subsequently emit light of a specific wavelength that is detected by 
the instrument. Currently, the industry standard flow cytometers allow the simultaneous 
detection and separation of four fluorochromes, making it possible to examine the 
expression of up to four different proteins on a cell. Traditionally, flow cytometry has 
been used to examine cell-surface proteins; however, methods have been developed to 
allow the use of this method for examination of intracellular proteins. This often 
involves first staining the cells with antibodies against cell-surface molecules in order to 
be able to electronically isolate subsets of cell populations. Nonetheless, as in 
microscopy, it is difficult to detect poorly expressed intracellular/intranuclear proteins 
(such as GFIlB) using this method because of the background produced upon fixation of 
cells after surface staining. We tested several methods of fixing and permeabilizing cells 
(22;23) with limited success before finding and adapting the method described here. 
These procedures are readily amenable to the detection of other nuclear transcription 
factors. 
We have adapted flow cytometric methods, which can be easily performed by lab 
personnel with minimum working knowledge of bench top flow cytometry instruments, to 
detect nuclear proteins using polyclonal antibodies. We have used standard techniques 
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for staining the surface of cells, and have modified techniques for fixing the surface stain 
and permeabilizing both the cellular and nuclear membranes. Additionally, we have 
adapted a method for isolating nuclei (24) in order to determine whether a stain is 
nuclear or cytoplasmic. Together, these techniques provide a fast, easy alternative to 
classical methods for the detection of intracellular proteins and the determination of 
subcellular localization. 
Materials and methods. 
Mice and preparation of cell suspensions. Mice were housed in the Baxter Barrier 
facility at the University of Louisville Medical School. All animal protocols were 
approved by the University of Louisville Institutional Animal Care and Use Committee 
(IACUC). 
Thymi of 4-8-week-old mice were removed into Hank's Balanced Saline Solution 
plus 2% heat inactivated fetal bovine serum (HBSS~FBS) and disrupted between the 
ends of glass slides. The cell suspension was passed through Nytex mesh to remove 
debris, and sedimented in a Sorva1l7 centrifuge at 1200 rpm. The cell pellet was washed 
by resuspension in 10 mL of HBSS~FBS and sedimented as described. Cells were 
resuspended in 10 mL ofHBSS~FBS and counted using a Coulter Z2 Particle Counter. 1 
x 106 cells were aliquoted into pre-labeled Falcon 2008 tubes for each stain to be 
performed. 
Surface staining. Surface proteins were detected using a standard protocol. Briefly, 
ali quoted cells were washed once with F ACS® media (HBSS with 0.1 % BSA, 0.1 % 
Sodium Azide, and 0.036% Sodium Bicarbonate), and spun as described. The 
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supernatant was poured off, cells were resuspended in 100 JlL of F ACS® media, and 20 
JlL of the appropriate antibody dilution was added (see below for antibody dilutions). 
The cells were incubated for 20 minutes at 4°C in the dark, washed once with F ACS® 
media and placed on ice. 
Fixing and intracellular/intranuclear staining. After surface staining and washing, 
cells were washed once with phosphate buffered saline without calcium or magnesium 
(PBS-), then resuspended in 100 JlL ofPBS-. A vial of 16% formaldehyde (Polysciences 
catalog #18814) was opened, and a 4% solution was made by dilution into PBS-; the 
formaldehyde stock was discarded. 100 JlL of 4% formaldehyde was added to each tube 
of cells while gently vortexing. The cells were covered with aluminum foil and 
incubated on ice for 3 hours. Cells were washed twice with PBS-, and resuspended in 
100 JlL of stain buffer (PBS- plus 5% FBS and 0.5% TritonX-100). The cells were 
covered and incubated on ice for 30 minutes, after which time 20 JlL of the appropriate 
primary antibody dilution was added. The cells were gently mixed and incubated on ice 
for 30 minutes, covered. Cells were washed once with stain buffer, resuspended in 100 
JlL of stain buffer, and 20 JlL of secondary antibody was added. The cells were covered 
and incubated on ice for 30 minutes. Finally, cells were washed with stain buffer and 
resuspended in 250 JlL of stain buffer for data acquisition. All solutions were kept on ice. 
Permeabilization and staining of unfixed cells. Cells were aliquoted and washed with 
F ACS® media as described for surface staining and resuspended in 100 JlL of F ACS® 
media with 0.03% saponin (F ACS plus saponin) (22). 20 JlL of the appropriate primary 
antibody was added to each tube, and the cells were incubated at 4°C in the dark for 30 
minutes. Cells were washed once with F ACS plus saponin, and resuspended in 100 JlL 
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of F ACS plus saponin. 20 J..lL of the appropriate secondary antibody dilution was added, 
and the cells were incubated for 30 minutes at 4°C in the dark. Finally, cells were 
washed once with F ACS plus saponin and once with F ACS® media. The cells were 
resuspended in either 250 J..lL of F ACS® media or 250 J..lL of nuclear isolation media 
(NIM; F ACS® media plus 1 mM EDT A and 0.5% NP-40). All wash steps were in 2 mL 
of media. 
Antibody panels and dilutions and flow cytometry. Surface staining was performed 
using anti-CD4 (RM4-5)-APC and anti-CD8 (53-6.7)-PE, both from Pharmingen. 
Antibodies were diluted together into F ACS® media, with a dilution factor of 1: 100 for 
each antibody. For intracellular/intranuclear staining, antibodies were diluted using the 
permeabilization buffer appropriate for the method and were used at the following 
dilutions: goat polyclonal anti-GFIl (sc-8558, Santa Cruz Biotechnology) at 1 :10, goat 
polyclonal anti-GFIlB (sc-8559) at 1 :50, and normal goat IgG (sc-2028) at 1 :25 and 
1:125 for GFIl and GFIlB controls, respectively; rabbit polyclonal anti-EGR1 (sc-189) 
at 1 :200 (23), and normal rabbit IgG control (sc-2027) at 1 :400. Dilution factors for IgG 
control antibodies were based on the final J..lg quantity of the experimental antibody used. 
Secondary antibodies, bovine anti-goat FITC (sc-2348) and donkey anti-rabbit FITC 
(711-096-152, Jackson Laboratories), were used at a 1 :100 dilution. Anti-BCL2-FITC 
and its FITC conjugated isotype control (catalog #554221, BD Pharmingen) were used at 
a 1 :33 dilution. Flow cytometry was performed on a Becton Dickinson F ACSCaliburTM 
flow cytometer, and analysis was performed using FlowJoTM (TriStar) software. 
Fluorescence Microscopy. Green fluorescence protein (GFP) transgenic mouse 
thymocytes were sorted to >95% purity for positive GFP fluorescence on a F ACS 
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Vantage Cell Sorter (Becton Dickinson) using 488 nm excitation and standard FITC 
emission optics. 700,000 sorted thymocytes were stained with 5 uM Hoechst 33342 in 
F ACS® media for 30 minutes at 37°C. Stained cells were divided into two equal parts, 
pelleted, and resuspended in 100 ilL of F ACS® media or NIM. A wet mount of 50 ilL of 
each sample was analyzed for GFP (cytoplasm) and Hoechst fluorescence (nuclei) on an 
Olympus IX50 fluorescence microscope. 
Results and discussion. 
BeL2 and EGRI confirm valid fixation of surface stain and permeabilization. 
We were interested in using flow cytometry to detect nuclear transcription factors 
that are expressed at low levels within thymocyte subsets. We started with commercially 
available antisera to the GFIlB transcription factor. Though unfixed GFIlB transgenic 
thymocytes showed GFIlB-positive staining when permeabilized with 0.03% saponin, 
we were unable to detect positive staining if cells had been fixed in a solution of 1 % 
formaldehyde (Polysciences catalog #04018) in HBSS despite attempts to permeabilize 
with 0.03% or 0.3% saponin, and 0.1 % or 0.5% TritonX-100 (22;23). We therefore 
purchased an EM-grade formaldehyde (Polysciences catalog #18814) that is supplied in 
individual 10-mL aliquots. The formaldehyde was stored in the dark, and a vial was 
opened immediately prior to use. The unused portion was discarded, limiting the 
exposure of the reagent to light and to oxidizing substances in the air. By so limiting the 
degradation of the formaldehyde, we decreased the autofluorescence of the fixed cells 
(25), thereby increasing our signal-to-noise ratio and allowing detection of transcription 
factors in thymocyte subsets. 
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To ensure the accuracy of our results, we examined proteins with established 
expression patterns and cellular localization. By confirming the known expression 
profile ofBCL2 (26) (Figure 4), we were able to determine that our fixation and 
permeabilization methods do not disturb antigen-antibody interactions. Moreover, 
detection of the nuclear transcription factor EGRI (27) using the same protocol served as 
a control for permeabilization of the nuclear membrane (Figure 4). In sum, our 
adaptation of established permeabilization and fixation techniques allows sensitive and 
accurate detection of intranuclear antigens without disrupting membrane or cytoplasmic 
staining. 
GFIlB is not detectable in most thymocytes of wild-type mice. In fact, utilization 
of the sensitive methods described here allowed detection in only the relatively rare 
CD44- DN subsets (19). Therefore, wild-type thymocytes served as negative controls for 
staining with anti-GFIlB (data not shown), further confirming the specificity of our 
reagents and methods. 
Isolation and analysis of nuclei confirm nuclear localization of transcription factors. 
F or our experiments it was necessary to confirm nuclear localization of our 
transgenic transcription factors. To accomplish this task, we adapted a method that has 
historically been used to study nuclei for DNA content (24). 
Unfixed cells were permeabilized and stained as described, then resuspended in 
either F ACS® media or NIM for the isolation of nuclei. The removal of the cytoplasm 
was confirmed separately by microscopic analysis of sorted GFP-positive thymocytes 
that had been stained with the DNA dye Hoechst 33342 and resuspended in either F ACS 
or NIM (Figure 5), and for stained cells by a change in forward and side scatter properties 
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Figure 4. Intracellular/intranuclear staining of fixed thymocytes. Shown is a 
representative F ACS plot of surface-stained, fixed, permeabilized and intracellularly 
stained thymocytes. Gates are drawn around each of the four major subsets, and are 
labeled as DN (double negative), DP (double positive), CD8 (CD8 single positive), and 
CD4 (CD4 single positive). The expression of BCL2 and EGRI was examined by 
intracellular/intranuclear staining and the results are shown in histogram format. In each 
histogram overlay, the dotted line represents staining with the control IgG and the solid 
line represents the experimental stain. As expected, BCL2 is expressed highly in CD4, 
CD8, and most DN cells, and at low levels in DP cells. A positive shift in fluorescence in 
the presence of the anti-EGRI antibody occurred in all thymocyte subsets, though the 
range of expression level is larger in DN thymocytes as indicated by a broader histogram. 
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Figure 4 
CDB---______+ BCL2 ---~, EGR1---~ 
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(data not shown). Permeabilized and stained cells and nuclei were analyzed by flow 
cytometry for a positive shift in fluorescence intensity. Figure 5 shows histogram plots 
of cells (top) versus nuclei (bottom) for BCL2, EGRl, GFIlB, and GFIl (left to right). 
Each histogram overlay includes both the experimental stain (solid bold line) and the 
corresponding IgG control (dashed line). The stains for BCL2 and EGRl were 
performed using wild type thymocytes, while those for GFIlB and GFIl were performed 
using thymocytes from mice that were transgenic for GFIlB or GFIl, respectively. 
BCL2, which localizes to the mitochondria, was included as a cytoplasmic control. 
Total thymocytes (cells) show variable expression of BCL2, mirroring the expression 
profile in thymocyte subsets. However, isolated nuclei do not show any positive staining 
for BCL2, as the mitochondria are removed with the cytoplasm during the nuclear 
isolation step. Results are shown for EGRl, GFIlB, and GFIl. The intensity of signal 
for an intranuclear stain depends on both the affinity of the antigen/antibody interaction 
and the abundance of the protein within the nucleus of a cell. The slight shifts for GFIlB 
and GFIl, both expressed from transgenes, is likely due to a relatively low affinity of the 
polyclonal antibodies available to detect them. In all stains performed, the overall shifts 
of both the IgG control and the experimental stain decrease upon isolation of nuclei, 
likely due to a loss of autofluorescence from cytoplasmic proteins. However, the stain 
for each transcription factor retains its shift above background in intact nuclei, while the 
shift for BCL2 disappears. Taken together, these data suggest that flow cytometry is a 
reliable method for determining nuclear localization of proteins. 
We have developed and described companion methods for l) detecting poorly 
expressed proteins in subsets of heterogeneous cell populations using low-affinity 
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Figure 5. Retention of nuclear stains upon removal of cytoplasm and cellular 
membrane. Microscopic analysis of Hoechst-stained GFP-positive thymocytes 
confirmed removal of cytoplasmic contents upon resuspension in NIM. The F ACS 
image (cells) represents merged GFP/ Hoechst fluorescence while the NIM image is only 
the Hoechst fluorescence. No GFP fluorescence was observed in isolated nuclei. 
Histogram overlays indicate the expression of BCL2, EGRI, GFIlB, and GFIl, (left to 
right) in total thymocytes. The overlays include the specific IgG control for the 
experimental antibody (dashed line) and the experimental stain (bold line). Plots for 
intact cells are shown above plots for isolated nuclei. The nuclei are negative for BCL2, 
but positive for EGRI, GFIlB, and GFIl. Note: Microscopy performed by Michael K. 
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polyclonal antibodies and 2) confirming nuclear isolation of transcription factors. These 
methods combine to provide simple, reliable, and fast alternatives to traditional methods. 
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CHAPTER III 
GFIlB EXPRESSION LEADS TO DEFECTS IN T-CELL ACTIVATION, IL7-Ra 
EXPRESSION AND T-CELL LINEAGE COMMITMENT 
Introduction. 
T cell differentiation in the thymus is dependent upon signaling through the T 
Cell Receptor (TCR) and is characterized by the resulting changes in expression patterns 
of CD4 and CDS surface coreceptor molecules. Early thymocyte precursors are CD4" 
CDS" (double negative, DN) and are signaled to differentiate first into CD4+CDS+ (double 
positive, DP) thymocytes. Further differentiation ofDP thymocytes into mature CD4+S" 
single positive (CD4 SP) or CD4"S+ (CDS SP) T cells is triggered by the engagement of 
TCRs on the immature TCRhiCD4+CDS+ thymocytes by self-peptidelMHC complex on 
thymic epithelial cells (2S;29). Negative selection eliminates immature DP thymocytes 
through clonal deletion of those T cells that have high affinity for self peptide and thus 
are potentially autoreactive (30). Positive selection occurs when low-affinity TCR-
ligand interactions trigger a signal for survival and results in termination of one or the 
other CD4 or CDS coreceptor molecule. The choice of which coreceptor to extinguish is 
referred to as lineage commitment. 
The Growth Factor Independence-l (GFIl) and GFIlB proteins are closely 
related nuclear oncoproteins that may regulate cytokine pathways. Gfil was originally 
identified as the gene upregulated by insertion of Moloney murine leukemia virus 
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(MoML V) in a thymic lymphoma that was selected for its ability to grow in the absence 
of the T-cell cytokine IL-2 (8). Forced expression ofGFIl in the IL-2-dependent 
parental cell line potentiates the outgrowth oflL-2 independent cell lines, without 
inducing IL-2 (8;9). Gfil B was identified by low stringency hybridization screening with 
a cDNA probe encoding the zinc-fmger region of Gfil (10). GFIl and GFIlB are 97% 
homologous in the carboxy-termina1165 amino acids that code for six Cys-His zinc-
fingers. An amino-terminal 20-amino-acid SNAG domain, responsible for nuclear 
localization and transcriptional repressor function, is also highly conserved (9). In 
contrast, the 236 intervening amino acids between the GFIl SNAG and zinc-finger 
domains bear no homology to the corresponding 145 amino acids ofGFIlB. Both 
proteins bind to virtually identical DNA consensus sequences and function as 
transcriptional repressors in a SNAG-dependent manner (9;10). GFIl is mildly anti-
apoptotic and inhibits growth arrest ofIL-2 dependent T cell lines under conditions of 
limiting IL-2 (9;31), while GFIlB inhibits both IL-6-induced differentiation and growth 
arrest ofMl myelomonocytic cells (10). Mice deleted for Gfil have altered 
inflammatory responses and differentiation in the myeloid lineage (17), while mouse 
embryos deleted for Gfil B die in utero due to a lack of definitive erythropoiesis (18). 
Gfil and GfilB are differentially expressed in lymphoid compartments. Northern 
analysis reveals that Gfil is expressed in the bone marrow and thymus, with low-level 
expression in the spleen, whereas Gfil B is expressed in the bone marrow and spleen, with 
low-level expression in the thymus (10). Both Gfil and GfilB show regulated expression 
during T cell development, but Gfil B expression is terminated in mature thymocytes. 
Gfil message is not expressed in Go splenic T cells, but is induced upon T cell activation 
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(8;20). Transgenic expression ofGFIl and GFIlB in T cells allowed us to determine the 
functional basis for differential expression of these factors. Transgenic expression of 
GFIl potentiates T-cell activation. In contrast, ectopic expression ofGFIlB in T cells 
results in defective T-cell activation, lower numbers of peripheral T cells, a reduction in 
IL-7Ra expression and a developmental block to CD8 SP T cells. The block to CD8 SP 
development is mitigated by forced expression of BCL2 or GFIl. These data indicate 
that GFIl and GFIlB are not redundant for T cell activation function, and implicate 
integration of activation and survival signaling in CD8 lineage commitment. 
Materials and Methods. 
Mice. The generation of the ed2-Gfil transgenic mice has been described (20). The lek-
Gfil transgenic mouse (line 3A) was generated by cloning the rat Gfil cDNA into the 
BamBI site of the TLC vector (32). This vector contains a 3.2-kb fragment of the mouse 
lek proximal promoter and a 2.2-kb fragment of the human growth hormone (GH) gene, 
which provides exons and introns for splicing and polyadenylation sequences. A 2.2-kb 
fragment of the 3' locus control region of the human CD2 gene is located downstream of 
the GB to obtain copy-number- and insertion-site-independent levels of expression. The 
GFIIB transgenic mice (lines 5B and 5C) were constructed in an identical manner to the 
GFIl transgenic except the construct contained the cDNA for mouse Gfil B inserted into 
the BamBI site. The GFIl and/or the GFIlB transgene (1 to 5 nglJ.lI) was microinjected 
into C57BLl6J (Jackson Laboratory) eggs according to standard methodology in the 
Laboratory of Immunopathology, NIAID, NIH. 
34 
RAG2-1-IHY mice (Taconic), and EJ-l-BCL2-25 transgenic mice (Jackson 
Laboratory) (33) were purchased from commercial vendors. All mice were on a 
C57BLl6 J background and bred in the Baxter Barrier animal care facility at the 
University of Louisville School of Medicine and housed under specific pathogen-free 
conditions. GFIl and GFIlB transgenic daughters who were heterozygous for the RAG 
mutation, as well as the HY TCR transgenes were then backcrossed with their RAG2-1-, 
HY TCR+ fathers. Colonies were expanded by intercrossing oflittermates. BCL2/GFIlB 
and cd2-GFIl/GFIlB bi-transgenics were generated in a similar manner. All animal 
work performed was reviewed and approved by the University of Louisville Institutional 
Animal Care and Use Committee. 
Antibodies. Antibodies with the following specificities were used for cell stimulations: 
CD3E (l45.2Cll) and CD28 (37.51). Antibodies with the following specificities were 
used for staining of thymocytes and splenocytes: CD4 (RM4-5 and GK1.5), IL-7Ra. 
(A7R34; eBiosciences), CD8a (53-6.7), CD3E-( 145-2Cll), TCR-a~ (H57-597), TCR 
V~8 (F32), CD24a-(Ml/69), CD69 (H1.2F3), and CD25 (PC61). Antibodies were 
purchased from BD-Pharmingen unless otherwise noted. Intranuclear staining was 
performed using anti-GIFIB goat polyclonal IgG (sc-8559), anti-GFIl goat polyclonal 
IgG (sc-8558), normal goat IgG (sc-2028) control, and secondary bovine anti-goat IgG-
FITC (sc-2348), all from Santa Cruz Biotechnology. 
Preparation of Cell Suspensions. Thymi from 4- to 6- week-old mice were removed 
and disrupted between frosted ends of glass slides and washed twice with Medium 199 
(Gibco BRL Life Technologies, Gaithersburg MD). Cells were obtained from spleens by 
perfusion with 10 ml Medium 199. Both thymocyte and splenocyte cell debris was 
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depleted by passage through Nytex nylon mesh screens. Splenocytes were treated with 
ammonium chloride-potassium bicarbonate (ACK) solution (150mM NH4CI and 10 mM 
KHC03) to lyse red blood cells. For experiments requiring isolation ofT cells, splenic 
cell preps were depleted of other cell types by the use of T cell enrichment columns 
(R&D Systems). All cells were counted with a Coulter Counter model Z2 (Coulter, 
Miami FL) and viability assayed by trypan blue exclusion. 
Flow Cytometric Analysis. Cell surface staining was performed by incubating 1 x 1 06 
cells with mAbs at varying concentrations in F ACS® media (HBSS with 0.1 % BSA, 
0.1 % Sodium Azide, and 0.036% Sodium Bicarbonate) for 20 min on ice. Stained cells 
were washed twice with F ACS® media and fixed in 1 % formaldehyde (Polysciences, 
Warrington, PA). For intracellular staining, cells were fixed in 2% formaldehyde in PBS 
and permeabilized and stained in PBS + 5% fetal bovine serum and 0.5% Triton x-tOO. 
Flow cytometry was performed on a F ACSCaliburTM, F ACSV antageSE, or F ACStar 
flow cytometer using standard CELLQuestTM acquisition. Data were analyzed using 
CELLQuestTM (Becton Dickinson) and FlowJoTM (TreeStar) software. The absolute 
cell numbers of gated cells per thymus or spleen were calculated by multiplying the 
percentage of each population with the total number of cells per thymus or spleen 
respectively. 
Northern, Western and RT -peR Analyses. RT -PCR analyses were performed as 
previously published (34;35). The sequences of the Gjil-specific primers were 5'-
CACACCTTCATCCACACAGG-3',5'-GATGAGCTTTGCACACTGGA-3', and the 
probe was 5'-TACCGTGAGGATGTCTTCCC-3'. The sequences of the GjilB-specific 
primers were 5'-AGCACAGAGTCTCCCTTGGA-3', 5'-
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CAAAGGTTTTGCCACAGACA-3', and the probe was 5'-
ACCCCTCATGGGCTAGAAGT-3'. The GfilB pattern was confirmed with the primers 
5' -GAGCAGCATACTCACGTCCA-3', 5'-TTCATGTCCGACTTCTGGTG-3', and the 
probe was 5'-CAAAGCCTTCAAGCGTTCAT-3'. 
Western blotting with antibodies against GFIl (sc-6357), GFIlB (sc-8559, Santa 
Cruz)), GFIl and GFIlB (sc-6357), p27 (BD Pharmingen 554069) and IRF1 antibody 
(sc-640) was performed as follows. Single cell suspensions of primary thymocytes were 
lysed at a concentration of 10-20 x106 cells/lOOJ,l1 SDS lysis buffer (25 mM Tris pH 7.5, 
10% glycerol, and 2% SDS supplemented with Protease Inhibitors Complete (Roche) and 
2mM PMSF. Protein concentration was determined using the BCA Protein Assay 
Reagent (Pierce, Rockford IL), and 75 J,lg of cellular extract was run on a 10% SDS-
polyacrylamide gel, transferred to Immobilon-PVDF (Millipore, Bedford, MA) and 
blocked for 1 hour at room temperature (RT) in blocking buffer (5% milk, 20 mM Tris, 
pH 7.3, 6.85 mM NaCi, 0.1 % (v/v) Tween-20, 0.5 gIL MgCI2). Membranes were 
incubated overnight at 4°C in primary antibody diluted in 5% protease-free BSA (Fisher 
Biotech, Pittsburgh, P A), then HRP-conjugated secondary antibody (Amersham) for one 
hour at RT. Blots were developed using ECL reagents (Amersham,). For Western 
analysis of sorted thymocytes and purified T cells, 1x106 cells were resuspended in 15 J,ll 
of lysis buffer (50 mM HEPES pH 7.8, 450 mM NaCI, 0.2 mM EDT A, 25% glycerol, 1 % 
NP40 (36), Protease Inhibitors Complete (Roche), and 2 mM PMSF), then sonicated 
using a Misonix Sonic Dismembrator with microprobe tip. 4X loading buffer was added, 
and the lysates were boiled. The entire contents of the lysate were loaded onto a 
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denaturing SDS polyacrylamide gel, and Western blotting was performed as described 
above. 
Cell Stimulation and Proliferation. Single cell suspensions of spleen cells in RPMI 
1640 (Gibco BRL Life Technologies, Gaithersburg, MD) supplemented with 5% fetal 
bovine serum, L-glutamine, penicillin, streptomycin, gentamycin, 2% HEPES (all from 
Gibco BRL Life Technologies) and 0.1% 2-mercaptoethanol (Sigma) were plated in 96-
well round-bottom plates (Corning, Corning, NY) at a density of lxlO5 per well in 100 
,.11. Stimuli were added as indicated at a range of concentrations to assess dose 
dependency. The stimuli were low-endotoxin, no-azide anti-CD3 (145.2Cll), anti-CD28 
(37.51) (both antibodies from Pharmingen, San Diego, CA), and recombinant human IL-
2 (Chiron, Emeryville, CA). Cells were cultured for 48 or 72 hours, then pulsed with 
eH]thymidine (I~Ci) (Amersham, Piscataway, NJ), and harvested 18 hours later using a 
TOMTEC-Harvester961 Model Mach II (Wallac, Akron, OH). Proliferation was 
determined by measuring radioactivity (Wallac 1205-SP2 Betaplate Counter). 
Coreceptor Reversal. Purified DP thymocytes (>96%) were obtained by panning with 
IgM anti-CD8 (83-12-5) coated plates. DP thymocytes (5 x 106/ml) were first placed into 
"signaling cultures" and stimulated for 12-18 hours with a combination ofphorbal-12-
myristate-13-acetate (0.6 nglml) and ionomycin (0.6 ~glml)(P+I; Calbiochem) (37). At 
the conclusion of signaling culture, cells were harvested, washed, and placed into 
nonstimulatory "recovery cultures" for an additiona112-16 hr. Cells were stained for 
CD4 and CD8 expression and CD4+CD8- cells were obtained by electronic sorting of the 
stained cells. The purified CD4+8- cells were further cultured in "postrecovery cultures" 
in the presence or absence of 6 nglml recombinant mouse IL-7 (Calbiochem, San Diego, 
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CA) overnight, after which they were harvested and stained for CD4 and CD8 
expression. All cultures were performed at 37°C in 5% C02 humidified air atmosphere 
in RPMI 1640 supplemented with 5 x 10-5M 2-mercaptoethanol and 10% FCS that had 
been depleted of endogenous steroids by pretreatment with 0.5% Norit A charcoal and 
0.05% dextran for 30 min at 56°C. 
Results. 
Gftl and GftlB are regulated during T lymphopoiesis. 
We examined the steady-state mRNA levels ofGji1 and Gji1B during T 
lymphopoiesis (Figure 6A). Thymocyte populations were sorted, RNA was extracted, 
and reverse transcriptase-polymerase chain reaction (RT-PCR) was performed to detect 
ribosomal S16 expression (34;35). The products of the reaction were analyzed by 
Southern blot with a radiolabelled 816-specific oligonucleotide probe. The signal was 
quantified by phosphorimager, and the samples were normalized to obtain equivalent 816 
signal from each template. Subsequent analysis of Gji1 expression in the 816-normalized 
cDNA templates revealed low-level signal in CD4"CD8-CD44+CD25- cells (DN1) and 10 
fold greater levels in CD4"CD8-CD44+CD25+ (DN2) thymocytes. The transition between 
DNI and DN2 corresponds to T lymphocyte lineage commitment. Signal intensity from 
the Gji1 RT-PCR product gradually increases to double the DN2leveis at the 
CD4+CD8+TCRhi stage, which contains cells that have been recently positively selected 
and are about to undergo lineage commitment. Gji1 RT-PCR product levels then 
decrease 10 fold in CD4 and CD8 single positive thymocytes. In striking contrast, the 
signal levels of probed and quantified Gji1B RT-PCR product were low, but increased at 
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Figure 6. Expression of endogenous GFIl and GFIlB. A. Blotted and probed RT-
PCR analyses of Gfil and Gfil B in reverse-transcribed thymocyte-subset eDNA 
templates. eDNA templates were normalized for equivalent signal from blotted, probed 
S16. Primer/probe pairs for Gfil and GfilB were applied to the normalized eDNA 
templates to determine the relative Gfil and GfilB RT-PCR product levels in thymocyte 
subsets. Note: These data were generated by Dr. Sabine Herblot and Dr. Trang Hoang 
(Research Institute of Montreal, Montreal, Quebec) using PCR primers and conditions 
designed and optimized by Loretta Doan. B. Western blot analysis of sorted thymocyte 
subsets. 1 x 106 sorted cells of each subpopulation were lysed, and the total lysate was 
probed with anti-GFIl (top panel) or anti-p27 (bottom panel) as a loading control. GFIl 
protein levels are moderate in DP thymocytes and intermediate CD4+CDSlo cells, but 
increase in mature CD4 and CDS SP cells. Note: These data were generated jointly by 
Loretta Doan and Dr. Mary Kate Kitay. C. Flow cytometric analysis ofGFIl expression 
in thymocyte subsets. Intranuclear staining of surface stained fixed thymocytes yielded 
an expression profile for GFIl similar to that observed in C. Specifically, the level of 
GFIl protein increases in SP thymocytes. The pattern of GFIl expression in DN 
thymocytes has been published (36). D. Flow cytometric analysis of GFIlB expression 
in thymocyte subsets. Intranuclear staining of surface stained fixed thymocytes revealed 
expression of GFIlB in the relatively rare CD4-CDS-CD44- populations of cells. The 
average change in mean fluorescence intensity is indicated below each graph, and is 
defined as ~MFI=(MFIGFIlBIMFIIgG)xlOO (+/-SEM). GFIlB transgenic CD4-CDS-CD44-
thymocytes have a higher MFI in comparison to WT cells; whereas RAG2"'- thymocytes, 
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stages corresponding to T cell receptor beta-chain selection (DN3), and positive selection 
(DP TCRhi). In the thymus, Gfil expression is gradually induced upon induction of the T 
cell differentiation program, whereas low-level Gfil B expression correlates with positive 
selection events. 
GFIl and GFIlB are expressed in normal thymocytes. 
To examine the level ofGFIl in thymocyte subsets we performed Western 
analysis on one million sorted DP, CD8 SP, CD4 SP and CD4+CD810 thymocytes (Figure 
6B). The level ofGFIl does not differ between the bulk ofDP thymocytes and those 
poised to make a lineage commitment step (CD4+CD8iO); however, the level of GFIl is 
dramatically higher in SP thymocytes. To confirm these data, we examined thymocyte 
expression ofGFIl by intranuclear staining and flow cytometry. As seen in the Western 
blot data, flow cytometric analyses revealed higher levels of GFIl protein in SP 
thymocytes (Figure 6C). The upregulation ofGfil message in DP thymocytes, with 
subsequent increase in GFIl protein in SP cells, suggests that GFIl may playa role in the 
transition between these two developmental stages. 
RT -PCR analyses revealed restricted expression of Gfil B in relatively rare 
thymocyte subsets (Figure 6A). Not surprisingly, Western analysis and intranuclear 
stains for GFIlB failed to reveal GFIlB expression in bulk thymocytes (data not shown). 
Therefore, we focused on a flow-cytometric analysis of the relatively rare CD44- DN3 
and DN4 thymocytes that appear to express the highest levels of Gfil B message (Figure 
6A). We first examined the DN3 and DN4 cells from GFIlB-transgenic mice (detailed 
below). A comparative 66% shift in mean fluorescence intensity (~MFI = 
MFIGFIlS/MFIIgG x 100) between the control IgG antisera and GFIlB-reactive antisera 
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indicates that GFIlB protein is present (Figure 6D). In a similar manner, analysis of the 
DN3 and DN4 cells from non-transgenic littermates revealed a 41 % shift in MFI between 
control and GFIlB-specific antisera stains (Figure 6D). 
The RT-PCR data (Figure 6A) indicate that GfilB expression correlates with 
positive selection events. To explore this correlation we examined thymocytes from 
RAG2-1- mice, which are arrested at the DN3 stage because they lack the pre-TCR 
selection signal that follows RAG-mediated rearrangement of the TCR-beta chain. Flow-
cytometric analyses reveal no difference in MFI between control and GFIlB-reactive 
antisera in RAG2-1- thymocytes (Figure 6D). These data indicate that signals from the 
pre-TCR may be required for GFIlB expression. 
Transgenic Expression of GFIl and GFIlB. 
GFIl and GFIl B bind the same DNA sequence and repress transcription in a 
manner dependent on the SNAG repressor domain (9; 1 0), suggesting the possibility that 
these factors are redundant. High-level transgenic expression of GFIl in the thymus 
results in a block to T cell development at a stage corresponding to selection of cells after 
successful formation of the TCR~ chain (36). Given the thymic phenotype ofGFIl 
overexpression, we constructed transgenic mice expressing GFIl or GFIlB in developing 
and mature T cells (Figure 7 A). Transgene-specific Northern analysis revealed that 
GFIl-transgenic founders had moderate expression while GFIlB-transgenic founders had 
higher levels of expression; representative lines are shown (Figure 7B). Western analysis 
of total thymocytes and of column-enriched splenic T cells indicates that the transgenic 
GFIlB protein is expressed in both the thymus and the periphery (Figure 7C). Finally, 
flow cytometric analysis of the GFIIB-transgenic thymocyte populations revealed 
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Figure 7. Expression of transgenic GFIl and GFIlB. A. Schematic representation of 
the GFIl- and GFIlB-transgene constructs. The rat cDNA ofGfil (8) and mouse cDNA 
of GfilB (10) was placed under the control of the lckproximal promoter and 2.2kb 
human CD2 enhancer, with human growth hormone (GH) gene (32). B. Northern blot 
analysis of total thymus or spleen RNA from representative GFIl (line 3A) and GFIlB 
(line 5B) transgenic lines hybridized with transgene-specific probes. Total RNA from 
transgenic animals revealed moderate levels of transgenic Gfil in both thymus and 
spleen, while transgenic GfilB is expressed at higher levels. C. Western blot analysis of 
transgenic GFIl B in thymic or column-purified splenic T-cell whole-cell protein extracts. 
Cell extracts from 2 control (WT) and 2 GFIlB-transgenic mice were analyzed by 
Western blot with an antibody specific for the last 20 amino acids of GFI 1 (cross reactive 
to GFIlB). Densitometric analysis revealed that transgenic GFIlB is expressed at five-
fold higher levels than is endogenous GFIl in non-transgenic littermate thymocytes. 
Lysates probed with antiserum against IRF-l act as a control for loading. D. Flow 
cytometric analysis of GFIlB expression in GFIlB-transgenic thymocyte subsets. 
Transgenic expression of GFIlB is observed in all thymocyte subsets, though the level of 
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transgenic GFIlB expression in DN, DP, CD8 SP and CD4 SP thymocytes (Figure 7D). 
To explore the subcellular localization of transgenic GFIl and GFIlB, the 
cytoplasm of permeabilized and stained thymocytes was removed using NP40. Stripping 
the cytoplasm resulted in a loss of signal for the mitochondria-localized BCL2, but did 
not alter the 8MFI ofthymocytes stained for GFIl or GFIlB (data not shown), indicating 
that the targets of the respective antisera are nuclear. Given that these antisera are specific 
for GFIl and GFIlB in Western analysis, our flow cytometric data indicate that 
transgenic GFIl and GFIl B are localized to the nucleus of T cells. 
Transgenic expression of GFIl enhances T cell response to CD3 crosslinking and 
IL-2. 
GFIl was previously shown to confer IL-2 independence to rat T-cell lymphomas 
(8;31). IL-2 is a critical T-cell cytokine during activation, and though peripheral 
lymphocytes do not express detectable levels of Gfil, activation signals induce Gfil 
within 30 minutes (20). Moreover, transgenic expression of GFIl was previously shown 
to mildly increase eH]-thymidine uptake given a fixed amount of CD3 crosslinking 
antibody (20). To further examine the effect of GFIl on T-cell activation potential, 
spleen cells from 4-6 week-old mice were stimulated by titration of a CD3-crosslinking 
antibody. T cells from mice expressing GFIl from either the Lck-promoter driven 
transgene (Figure 7 A), or a previously published CD2-promoter driven transgene (20), 
proliferated at a higher rate than T cells from control mice as evidenced by enhanced 
eH]-thymidine uptake (Figure 8A) and by increased numbers of cells in each cellular 
division as evidenced by CSFE staining (data not shown). 
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Figure 8. GFIl potentiates, whereas GFIlB inhibits, T-cell activation. A and B. 
Spleen cells from 4-6 week old GFIl transgenic mice (line 3A or a CD2 promoter-driven 
GFIl transgenic (20)) and nontransgenic littermate control mice were isolated and 
stimulated with either a dose titration of plate-bound antibody to CD3E (A) or a low level 
of anti-CD3E (0.06 J..lglml) and increasing amounts of human rIL-2 (B) and cultured for 
48 hours. eH] thymidine (1 J..lCi) was added and plates were incubated for 18 hours. 
Proliferation was measured as CPM of eH] thymidine incorporation. Error bars indicate 
standard error of the mean. Note: These data were generated by Dr. Michael Alexander. 
The results shown in Panel A were reproduced by Loretta Doan. C. Spleen cells from 4-
6-week-old GFIl transgenic mice, as well as littermate controls, were stained with 
antibodies to CD4 and CD8 then analyzed by flow cytometry. A representative F ACS 
profile is shown. No difference was observed in total number of splenocytes or in splenic 
T cell numbers between GFIl transgenics and littermate controls of either line. Note: 
These data were generated by Dr. Mary Kate Kitay and reproduced by Loretta Doan. D. 
Spleen cells from 4-6 week old GFIlB transgenic mice (lines 5B and 5C) were activated 
as in (A) for either 48 hours (left panel) or 72 hours (right panel) before the addition of 
eH] thymidine. E. Spleen cells isolated from 4-6-week-old GFIlB transgenic line 5B, 
as well as littermate controls, were stained with antibodies to CD8 and CD4 and analyzed 
by flow cytometry. A representative F ACS profile is shown. Absolute spleen cell 
numbers from all mice examined were determined and are expressed in the table below as 
cell numbers x 106 ± SEM in the table below. Note: These data were generated by Dr. 
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To dissect the response ofGFIl-transgenic splenic T cells to stimulation, we 
limited the amount of CD3 antibody, and added increasing amounts ofIL-2. Again, we 
found that cells from GFIl-transgenic mice proliferated more vigorously in response to 
stimulation than cells from non-transgenic littermates (Figure SB). A flow cytometric 
analysis of splenocytes from control and GFIl transgenic mice show equivalent absolute 
cell numbers of total splenocytes and T cell subsets as delineated by the markers CD4, 
CDS, TCR beta, and CD3E (Figure SC), or CD62L and CD44 (data not shown). 
Therefore, GFIl potentiates the response to CD3 and IL-2 stimulation. 
GFIlB transgenic mice display peripheral T lymphopenia and a profound defect in 
activation after CD3 cross-linking. 
We next looked at the response of GFIl B transgenic splenic T cells to stimulation 
with anti-CD3E and found that they neither died (data not shown), nor proliferated 
substantially. Spleen cells from 4-6 week-old mice from two GFIlB-transgenic lines (SB 
or SC, Figure SD) were stimulated by addition of increasing quantities of a CD3-
crosslinking antibody. T cells from GFIlB transgenic mice proliferated at a substantially 
lower rate than T cells from control mice as evidenced by eH]-thymidine uptake, even 
when the activated cells were given an additional 24 hours incubation (Figure SD, 4S 
hours versus 72 hours). 
An unanticipated potential explanation for this observation came from the finding 
that spleen cells from GFIlB transgenic mice show significant reduction in the numbers 
of CD4 and CDS T cells that could respond to CD3 stimulation (Figure SE). Mature CD4 
cells were reduced to 32% of wild type levels, while mature CDS cells were reduced to 
46% of wild type levels (Figure 8E). However, neither the TCR-expression level on 
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splenic T cells (data not shown) nor the total number of splenocytes (Figure 8E) was 
significantly reduced in GFIlB transgenic mice. Since both the GFIlB-transgenic lines 
gave equivalent data, we focused on the 5B line for further studies. 
The unresponsiveness of GFIlB lymphocyte populations to TCR-mediated 
activation signals could be due either to T lymphopenia or to a defect in signaling. To 
determine the mechanism, T cells were purified by negative selection, normalized to 
CD38 + T-cell numbers, and stimulated simultaneously with both anti-CD38 and anti-
CD28 in a co-receptor activation assay. Co-stimulated GFIlB-transgenic cells showed a 
marked inability to proliferate as compared to cells from non-transgenic littermates 
(Figure 9A). In addition, GFIlB-transgenics demonstrated decreased proportions of cells 
expressing activation markers CD69 and CD25 (IL-2 receptor a-chain) as compared to 
wild type cells (Figure 9B), as well as a decrease in fluorescence intensity of these 
markers on positive cells (data not shown). Therefore, GFIlB transgenic T cells are 
profoundly impaired in response to activation signals because of an intrinsic signaling 
defect, and not because of the overall reduction in CD38 + T cell numbers. These data are 
diametrically opposed to our findings for GFIl-transgenic mice, which showed enhanced 
response to activation. 
Transgenic GFIlB expression alters thymocyte lineage commitment and 
maturation. 
In order to determine the cause of peripheral T lymphopenia, we examined the 
thymus. Thymocytes were stained with antibodies against CD4, CD8, and TCR~ and 
analyzed by flow cytometry. In GFIlB transgenic mice, the number ofCD4 SP cells was 
considerably enhanced while there was a severe reduction in the development of CD8 SP 
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Figure 9. The GFIlB-induced inhibition of activation is cell autonomous and 
includes defective upregulation of early activation markers. A. 4 week old GFIlB 
transgenic and control splenic T lymphocytes were purified by negative selection, 
normalized for numbers of CD3+ T cells, and then co-stimulated with antibodies to CD3E 
and CD28. Proliferation was measured by eH] thymidine incorporation and the 
stimulation index (fold induction over non-stimulated controls) was calculated. A 
representative of 3 experiments is shown. Note: These data were generated by Dr. 
Michael Alexander. B. Splenocytes from GFIIB transgenic (open symbols, black 
background) and littermate controls (closed symbols, white background) were stimulated 
with antibodies to CD3 for 24 hours then stained with antibodies to CD4, CD8, CD25 
(circle) and CD69 (diamond) and analyzed by flow cytometry. CD4+or CD8+ events 
were gated, and the percentages ofCD25+ or CD69+ cells are depicted. Fewer GFIIB-
transgenic splenocytes exhibit induction of either CD25 or CD69. Bars = mean. Note: 
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Figure 10. Transgenic expression of GFIlB in the thymus results in enhanced 
numbers of mature CD4+ thymocytes and decreased CDS+ populations. A and B. 
Thymocytes from GFIIB transgenic and controllittermates were stained with antibodies 
to TCR~, CD4, and CD8, and analyzed by flow cytometry. The average number of total 
thymocytes x 106 ± SEM is expressed above the plots, with percentage of cells in each 
gate in (A). In (B) cells are gated on TCRint-hi events, and the CD4 versus CD8 FACS 
profiles are depicted. Thymocyte subsets are expressed as absolute cell numbers x 106 
per thymus ± SEM. Note: These data were generated by Dr. Mary Kate Kitay and 
reproduced by Loretta Doan. C. Thymocytes from 4-week-old GFIlB transgenic and 
controllittermates were stained with antibodies to CD24a, CD4, and CD8 and analyzed 
by flow cytometry. FACS profiles depicted are gated on CD4+ events. Absolute 
thymocyte cell numbers from all mice examined were determined and are expressed as 
cell numbers x 106 ± SEM. Note: These data were produced jointly by Loretta Doan and 
Dr. Mary Kate Kitay. 
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T cells (Figure lOA). The CD8 SP compartment contains both mature and immature 
intermediate single positive cells (CD8 ISP). CD8 ISP cells, in contrast to CD8 SP cells, 
do not have high level TCR expression. Therefore, the analysis was repeated through a 
TCRint-hi gate, which would include CD4 SP, CD8 SP thymocytes and their immediate 
precursors (39). The ratio of CD4+ to CD8+ cells was increased in the TCRint-hi 
population from a normal ratio of7:1 to a ratio of32:1 in the GFIlB-transgenic mice 
(Figure lOB). Therefore, few mature CD8 SP cells are generated in the GFIlB transgenic 
mice. Moreover, the lower numbers of CD8 SP cells provides a potential explanation for 
peripheral CD8 lymphopenia. 
We next examined the CD4 SP population. As CD4 SP thymocytes mature they 
downregualte CD24IHSA and exit the thymus. Therefore, the most mature CD4 SP 
thymocytes express low levels of CD24 and are relatively rare in wild type mice, while 
less mature CD4 SP thymocytes express higher levels of this marker (39-41). We found 
that the number of immature CD4 SP thymocytes (CD24hi) was relatively normal in 
GFIlB-transgenic mice; however, the number of mature CD4 SP thymocytes was 
increased five fold (Figure 10C). These data are supported by the surface expression of 
TCR~, Qa-2 and CD62L (data not shown), which also indicate that GFIlB-transgenic 
mice have greater numbers of phenotypically mature CD4 SP thymocytes. We have also 
examined the effects of the GFIlB transgene on a class II MHC null background to find 
that no CD4 SP cells were generated (data not shown). These data exclude the possibility 
that the increased CD4 SP cells are due to redirection ofMHC-class-I-restricted CD8 SP 
development into the CD4lineage. Altered signaling during activation in GFIlB 
transgenic thymocytes may lead to the accumulation of cells which should not normally 
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be selected (defective negative selection), or the accumulation of cells unable to mature 
and egress. 
The development of CDS SP T cells in GFIlB transgenic mice is not rescued by 
expression of the HY Class I restricted trans gene. 
It is unlikely that GFIlB represses CD8 or MHC class I expression since 
thymocytes from GFIIB-transgenic mice reveal normal surface expression ofCD8u and 
CD8~ in the DP fraction, and are not Class I-deficient (data not shown). To determine if 
the GFIlB block to CD8 development involved an alteration in TCR repertoire selection, 
GFIlB transgenic mice were mated to RAG2-1-/HY mice and resulting progeny were 
backcrossed to generate GFIlBI RAG2-1-/HY mice. The HY trans gene encodes a Class I-
restricted TCR that selects large numbers ofV~8+ thymocytes into the CD8+ T cell 
lineage in female mice (42). Because the Rag2 gene product is necessary for TCR 
rearrangement, all RAG2-1-/HY IGFIl B transgenic thymocytes express only the HY TCR 
as evidenced by V~8 staining (data not shown). Positive selection ofCD8+ T cells by the 
HY TCR was severely reduced in the RAG2-1-/HY/GFIlB female mice as compared to 
controls (Figure 11). Therefore, the critical defect in GFIl B transgenic mice is not 
simply an inability to form a class I restricted TCR. 
GFIlB expression overcomes a block to DP development imposed by autoreactive 
TCR signaling. 
To determine ifGFIlB-transgenic thymocytes display defective TCR signaling 
and/or activation in vivo we next examined the male RAG2-1-/HY/GFIlB mouse thymus. 
The HY TCR recognizes the male HY antigen when presented by H2-Db. Male HY 
transgenic thymocytes are blocked at the DN stage by auto-reactive HY TCR signaling 
56 
Figure 11. Expression of GFIlB inhibits the development of female HY -transgenic 
CDS SP T cells. Thymocytes from 4 week-old female RAG2-1-/HY and RAG2-1-
IHY IGFIl B mice were examined for the expression of CD4, CDS, and TCR V~S 
(utilized in the HY trans gene) by flow cytometry. Representative FACS plots are shown 
with the total number ofRAG2-1-/HY and RAG2-1-/HY/GFIlB thymocytes above the 
plots. Thymocyte subsets are expressed as absolute cell numbers X 106 per thymus ± 




112.6 ± 11.4 x 106 
c;> HYRAG'-OFIIB 
101.4 ± 9.2 x 106 
, ... ,...===-::==----. 
"'" 
10 ' OIl , .. '0000 10 ' OIl , .. ,""" 
CD8 CD8 
Thymocyte Subset WT 9:I~~ (~=2\ 0=4 
DN 6~:;~/1 10.97±2.0 DP 64.53±7.5 
CD4SP 0.08±O.0 0.67±O.1 
CD8SP 8.42±1.0 1.05±O.1 
58 
that mimics negative selection (43). Mutant mice with defective intracellular signaling 
overcome this block and accumulate V~8+ DP cells (44-46). GFIlB-transgenic 
peripheral T cells are defective in T-cell activation (Figures 8D and 9A). In agreement 
with these data, GFIlB-transgenic thymocytes overcome the block to development 
imposed by the autoreactive HY transgene, as shown by a modest four-fold accumulation 
ofCD8+ TCR~+ cells (11.1 % versus 47.9%) and a doubling of total thymus cellularity 
(Figure 12A and 12B). Therefore, our in vitro and in vivo data support a model in which 
ectopic expression of GFIlB leads to defective T cell activation. 
GFIlB impairs CD8 SP development in vitro, and decreases IL-7Ra expression. 
We have previously described an in vitro model system in which DP thymocytes 
can be signaled to differentiate into CD8 SP T cells (37). In this experimental system, 
signaled DP thymocytes initially terminate CD8 transcription, differentiate into CD4+8-
intermediate thymocytes, and upregulate surface expression of IL-7R. In the presence of 
IL-7, CD4+8- intermediate thymocytes terminate CD4 transcription and re-initiate CD8 
transcription (events referred to as 'coreceptor reversal') and ultimately differentiate into 
CD8 SP T cells (37). Consequently, we assessed the ability of signaled DP thymocytes 
from wildtype (WT) and GFIlB transgenic mice to differentiate in vitro into CD8 SP T 
cells (Figure 13 A). 
We isolated WT and GFIlB transgenic DP thymocytes (Figure 13A, Do) and 
stimulated them with phorbal-12-myristate-13-acetate (PMA) and ionomycin (P+I) as 
previously described (37). Signaled DP thymocytes from both WT and GFIlB transgenic 
mice were induced to differentiate into CD4+8- intermediate cells (Figure 13A, D2). 
Notably, in vitro generated intermediate CD4+8- cells from GFIlB transgenic mice 
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Figure 12. Expression of GFIlB overcomes a block to development in male HY-
transgenic T cells. Representative F ACS plots showing expression of CD4 and CDS (A) 
or CDS and TCR V~S (B) in male HY transgenic mice. Male RAG2-1-/HY/GFIlB mice 
show a 4-fold increase in the number ofCD4+CDS+ and TCR V~S+ thymocytes when 
compared to RAG2-1- HY littermates. The total numbers ofRAG2-1-/HY and RAG2-1-
/HY/GFIlB thymocytes are shown above the plots. Note: These data were generated by 
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Figure 13. GFIlB impairs co-receptor reversal. A. (DO) Purified CD4+CD8+ cells 
were obtained from pooled thymocytes of four 4-week-old GFIlB transgenic or four 
controllittermates by panning with anti-CD8 antibody, and subsequently stimulated with 
PMA and ionomycin (P+I) for 16 hrs at 37°C. Stimulated cells were stripped of their 
surface coreceptors with pronase protease, cultured in complete media overnight, stained 
for CD4 and CD8 expression and purified CD4+8- cells were obtained by cell sorting. 
(D2) Control (dashed line) and GFIlB transgenic (solid line) cells were analyzed by flow 
cytometry for IL-7Ra expression. Purified CD4 +8- cells (2 x 106) were cultured 
overnight in the presence of IL-7. Flow analysis of samples of each culture indicated 
CD4 and CD8 surface levels before (D3) and after pronase protease treatment and culture 
in complete media overnight (D4). Note: These data were generated by Dr. Qing Yu 
and Dr. Alfred Singer (Experimental Immunology Branch, National Cancer Institute, 
National Institutes of Health, Bethesda, MD 20892). B. Four week old GFIlB-
transgenic (solid line) and normallittermate control (dashed line) thymocytes were 
stained with antibodies against CD4, CD8 and IL-7Ra and analyzed by flow cytometry. 
Representative histograms comparing the IL-7Ra expression in thymocyte 
subpopulations are shown. Note: These data were generated jointly by Loretta Doan and 
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expressed lower surface levels ofIL-7Ra compared to cells from WT mice (Figure 13A, 
D2). We then added IL-7 to both populations of in vitro generated intermediate CD4+S-
thymocytes, and, after 24h, pronase stripped the cells to remove pre-existing CD4/CDS 
surface proteins so that we could determine the CD4/CDS proteins that the cells were 
actively synthesizing. Addition of IL-7 (Figure 13A, D3) followed by pronase stripping 
and re-expression culture revealed that 69.3% ofWT cells had undergone coreceptor 
reversal and differentiated into CDS SP T cells. In contrast, only 21.0% ofGFIlB 
transgenic cells had undergone coreceptor reversal to become CDS SP T cells (Figure 
13A, D4). Thus, GFIlB transgenic thymocytes at the CD4+S- intermediate stage of 
development are quantitatively deficient in their ability to undergo coreceptor reversal in 
response to IL-7 and are impaired in their ability to undergo in vitro differentiation into 
CDS SP T cells. 
To determine if the lower in vitro expression pattern of IL-7Ra on GFIl B 
transgenic thymocytes was a possible explanation for the defective CDS SP development 
in vivo, we next examined the expression of IL-7Ra in unmanipulated thymocytes. Cells 
were stained for CD4, CDS and IL-7Ra, then gated on thymocyte subpopulations and 
analyzed for IL-7Ra expression (Figure 13B). The level of IL-7Ra on DN thymocytes 
was not altered by the presence of the GFIlB transgene. However in both CD4 SP and 
CDS SP thymocytes, in which IL-7Ra expression is regulated by TCR signaling, GFIlB 
transgenic mice had lower levels of IL-7Ra than wild type littermate controls (Figure 
13B). Thus, GFIlB transgenic thymocytes are defective in both T cell activation and the 
expression of activation-induced genes such as CD25, CD69 and IL-7Ra. The lower 
level ofIL-7Ra on GFIlB transgenic thymocytes provides a potential explanation for 
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altered CD8 SP development in the GFIlB transgenic mice. Moreover, examination of 
peripheral T cell subsets revealed lower levels of IL-7Ra (data not shown). Since IL-7 
has been shown to regulate the survival of naIve CD4 T cells (47-50) the lack ofIL-7Ra 
expression is a possible explanation for peripheral CD4 T cell lymphopenia. 
Bi-transgenic BCL2/GFIlB mice generate CDS SP thymocytes. 
GFIlB-transgenic thymocytes express lower levels ofIL-7Ra (Figure 13B). IL-7 
maintains the expression of endogenous BCL2 in T-lineage cells (51). BCL2 does not 
support thymic positive selection in the absence ofMHC (52-54); however, transgenic 
expression of BCL2 can substitute for survival signals induced by cytokines such as IL-7 
(54). GFIlB-transgenic mice were mated to E~-BCL2-25 transgenic mice, in which the 
human BCL2 trans gene is expressed mainly in T lineage cells (33). As expected by the 
presence of the BCL2 transgene, total thymocyte cellularity was increased in bi-
transgenic mice (33); however, we found that BCL2/GFIlB bi-transgenics show 
increased numbers of TCRint-hi CD8 SP thymocytes and a normal ratio of CD4 SP to CD8 
SP thymocytes (Figure 14). While BCL2 may have pleiotropic effects on T-cell 
development (53), the ability ofBCL2 to rescue CD8 SP development in GFIlB-
transgenic mice is consistent with the role of BCL2 as a downstream target of IL-7. 
Bi-transgenic GFIl/GFIlB mice generate CDS SP thymocytes. 
We next determined whether GFIl could alter the defects engendered by GFIlB 
expression. GFIl enhances T cell activation whereas GFIlB impairs this process (Figure 
8). Since GFIl and GFIlB bind to the same DNA sequence, it is possible that some of 
the defects in GFIlB transgenic thymocytes are the result of an imbalance between DNA-
bound GFIlB versus GFIl. In fact, six-week-old GFIl/GFIlB bi-transgenic mice 
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Figure 14. Transgenic BCL2 restores CDS SP thymocytes in GFIlB transgenic 
mice. Thymocytes from GFIlB and BCL2/GFIlB bitransgenic littermates were stained 
with antibodies to TCRP, CD4, and CD8, and analyzed by flow cytometry. Cells are 
gated on TCRint-hi events, and representative CD4 versus CD8 F ACS profiles are 
depicted. A scatter plot ofCD8 SP cells in BCL2-transgenic, GFIlB-transgenic, and 
BCL2/GFIlB-bitransgenic mice reveals the increase in the CD8 SP population in the 
bitransgenic animals (in comparison to GFIlB-transgenic mice). Each diamond 
represents the percent of TCRint-hi CD8 SP cells per thymus of an individual mouse (5-7 
mice/group). The black bar is the mean value for each group. Note: These data were 
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Figure 15. Transgenic GFIl increases the generation of CD8 SP thymocytes in 
GFIlB transgenic mice. Thymocytes from 6-week-old GFIlB and GFIl/GFIlB bi-
transgenic littermates were stained with antibodies to TCRP, CD4, and CD8, and 
analyzed by flow cytometry. Cells are gated on TCRint-hi events, and representative CD4 
versus CD8 F ACS profiles are depicted. A scatter plot of CD8 SP cells in GFIl-
transgenic, GFIlB-transgenic, and GFIl/GFIlB-bitransgenic mice shows the partial 
restoration of CD8 SP thymocytes observed in bi-transgenic animals (in comparison to 
GFIl B-transgenic mice). Each diamond represents the percent of TCRint-hi CD8 SP cells 
per thymus of an individual mouse (4-6 mice/group). The black bar is the mean value for 
each group. The increase is statistically significant with a P value of 0.0003 as 
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generate twice as many TCRint-hi CD8 SP thymocytes than do littermate GFIlB 
transgenics (Figure 15, P = 0.0003). The lower level of expression of the GFIl transgene 
in comparison to the GFIl B transgene may explain the modest ability of GFIl transgene 
to compete with transgenic GFIlB. Nevertheless, GFIl expression increases the number 
of GFIlB-transgenic CD8 SP cells. 
Transgenic expression of GFIl does not alter other GFIlB-induced defects. The 
GFIlB-induced abnormal generation of phenotypically-mature CD4 SP thymocytes 
remains in the GFIl/GFIlB bi-transgenic thymus. Moreover, peripheral T lymphopenia 
in GFIlB transgenics is not altered by BCL2 or GFIl. It is known that BCL2-transgene-
induced elevation in thymocyte numbers does not alter peripheral T cell numbers (51). 
Likewise, we find that neither BCL2 nor GFIl increases the number of peripheral CD8 
SP T cells in the GFIl B-transgenic spleen. GFIl, like BCL2, appears to ameliorate only 
the GFI 1 B effect on the production of CD8 SP cells. The inability of either the BCL2 or 
GFIl transgene to cancel the GFIlB-induced alteration in the expression ofIL-7Ra (data 
not shown) indicate that both BCL2 and GFIl must act to increase CD8 SP generation by 
a mechanism that is independent of the induction of IL-7 signaling. However, it is 
formally possible that GFIl, like BCL2, acts downstream of IL-7 signaling and that 
transgenic expression of either protein mimics the effects of IL-7. 
Discussion. 
The phenotypes observed in GFIl and GFIlB transgenic mice can be understood 
in the context of the normal expression pattern of either factor. GFIl is induced at the 
transition between DP and SP cells. GFIl may thus playa role in the activation-induced 
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developmental steps between DP and SP thymocytes. GFIlB is induced at steps in 
thymocyte development in which thymocytes are activated. In fact, RAG2-1- cells that 
lack the ability to activate do not express GFIlB (Figure 6). GFIl and GFIlB have 
opposite effects on T cell activation. Peripheral GFIl transgenic T cells activate better 
than do those from wild type littermates, whereas GFIlB transgenic T cells are impaired 
in activation. Both phenotypes are cell autonomous as they occur in purified T cells from 
either transgenic (Figure 9 and data not shown). 
The impairment ofT cell activation function in GFIlB transgenic T cells appears 
to be linked to an inability to signal properly after TCR engagement and costimulation. 
First, purified GFIlB-transgenic T cells do not activate given CD2S- and CD3-
crosslinking antibodies (Figure 9A). Second, the TCR-signaling-dependent RASIMAPK-
induced expression of early activation markers CD25 and CD69 (55) is impaired in 
GFIlB transgenic T cells (Figure 9B). Finally, in male HY transgenic mice GFIlB 
expression rescues the generation ofDP thymocytes that are normally deleted due to 
strong autoreactive TCR signals (43). Similar results have been obtained in male HY 
transgenic mice that are rendered defective in TCR signaling by deletion of intracellular 
proteins that participate in the TCR-signaling cascade (44-46). However, the GFIlB-
induced defect in T cell activation cannot be restricted to proximal signaling molecules in 
the TCR- and costimulatory-signaling pathways, since GFIlB-induced impairment of 
CDS SP cell formation is also observed after in vitro drug-stimulated activation that 
bypasses the need for proximal TCR- and costimulatory-signaling events (Figure 13). 
The ability of GFIlB-transgenic thymocytes to respond to cytokine signaling may also be 
affected. Though activated GFIl B transgenic thymocytes fail to induce IL-7Ra 
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expression, transgenic expression ofIL-7Ra (56) did not change the GFIlB induced 
phenotypes (data not shown), whereas expression of the IL-7 downstream effector BCL2 
increased CD8 generation. Thus, GFIIB expression in T cells induces cell autonomous 
defects in intracellular signaling that may impair T cell activation at multiple steps. 
GFIl B may serve as a negative regulator of GFIl-enhanced activation. Both 
GFIl and GFIlB are expected to repress genes to alter the kinetics or activation potential 
of intracellular signals. The induction ofGFIlB in activated thymocytes could result in 
competition between GFIl and GFIlB for DNA binding at specific promoters. 
Alternatively, GFIl and GFIlB may regulate different promoters. Both scenarios appear 
to be relevant to the GFIlB-induced T cell defects. Since transgenic GFIl expression 
doubles the generation ofGFIlB-transgenic CD8 SP cells, GFIl and GFIlB may 
compete at promoters to regulate genes important for CD8 development. Target genes 
responsible for this phenotype may be properly regulated by GFIl, but improperly 
regulated by GFIlB in cells about to undergo lineage commitment. Interestingly, 
transgenic BCL2 or GFIl rescued CD8 SP development, but did not affect GFIIB-
induced changes in CD4 SP development, the expression of IL-7Ra or peripheral T 
lymphopenia. Target genes responsible for the latter GFIlB-induced phenotypes should 
be independent of GFIl regulation and instead uniquely regulated by GFIlB. 
GFIl and GFIlB differ in amino acid sequence in the region between the SNAG 
repressor domain and the zinc-finger DNA-binding domain. These dissimilar regions 
may mediate interaction with other proteins (such as other transcription factors or adapter 
proteins), leading to differential regulation of target promoters by GFIl and GFIlB. The 
normal role of GFI I B in the thymus may be to regulate the extent of GFI I-mediated 
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thymocyte activation during development. Our data are the first to demonstrate that GFIl 
and GFIlB are not redundant for T cell activation functions, providing a potential 
biological explanation for the termination ofGFIlB expression in mature T cells. 
IL-7 is critical for the survival and proliferation of immature thymocytes into 
mature CD8 SP cells (37;54;57). IL-7 is constitutively present in the thymus; however, 
IL-7Ra expression is not induced until TCR stimulation ceases (37). Thus, whether TCR 
signaling continues or ceases determines the ability to differentiate into CD8 SP T cells. 
This new perspective on lineage commitment is referred to as the "kinetic signaling" 
model. In accordance with this model, GFIlB-transgenic thymocytes, in which GFIl 
function is compromised, fail to integrate activation signals, resulting in impaired 
expression of activation-induced survival genes such as IL-7Ra (37). 
Models of lineage commitment which require quantitative or temporal differences 
in TCR signals to direct T cell development (58;59) would predict that the reduced 
activation in GFIl B-transgenic T cells should lead to improved CD8 SP development 
(60). Transgenic expression ofGFllB in the thymus instead results in a severe decrease 
in the generation of CD8 SP cells. A similar phenotype is exhibited by mice made 
deficient for interferon a,p signaling by knocking out the transcription factor IRF-l (61). 
These mice are devoid of CD8 SP T cells even though they contain normal numbers of 
CD4 SP T cells. We have established that the GFIlB-transgenic thymus defects are not 
due to GFIlB repression ofIRF-l (Figure 7C), CD8 or MHC Class I (data not shown), 
the absence of a functional TCR rearrangement (Figure 11) or to a TCR-signal-
independent redirection of CD8 cells to a CD4 lineage choice (data not shown). 
However, in agreement with the kinetic signaling model, a signal-independent survival 
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cue from the downstream target of IL-7, BCL2, increases CD8 SP generation in the 
context ofGFIlB expression. Therefore, the defect in generation ofCD8 SP cells in 
GFIlB-transgenic mice appears to be linked to an inability to transduce a post-activation 
signal-dependent survival cue. 
GFIl functions to inhibit T cell death induced by specific stimuli; GFIl increases 
survival of explanted thymocytes (62) and decreases apoptosis induced by TCR ligation 
(21). In GFIlB transgenic T cells, GFIl expression does not correct GFIlB-impaired 
expression ofIL-7Ra; however, like BCL2, transgenic GFIl increases CD8 SP 
generation in the GFIlB transgenic thymus. The salient function of GFIl in CD8 SP 
generation may be GFIl mediation of cytokine induced survival signaling that is impeded 
in GFIlB transgenic thymocytes. Taken together, these data are the first to suggest a role 
for GFIl in the integration of activation signals from the TCR with survival signals from 
cytokines such as IL-7. 
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CHAPTER IV 
GFIl IS AUTOREGULATORY IN T CELLS, BUT NOT IN A MYELOID 
LINEAGE CELL LINE 
Introduction. 
Growth Factor Independence 1 (G.fil) and G.filB are two closely related 
oncogenes that play different but pivotal roles in hematopoiesis. G.fil deficient mice 
display both thymic and peripheral T lymphopenia, with severe abnormalities in pre-T 
cell development (11; 16; 17). Furthermore, they display a profound defect in neutrophil 
differentiation, which leads to neutropenia (16;17). G.filB is necessary for the 
development of megakaryocytes and for definitive erythropoiesis (18). Deficiency of 
G.filB is embryonic lethal by day E15 (18). Given embryonic lethality, no thymic or T 
cell phenotype has been reported for G.filB deficiency; however, GFIlB transgenic mice 
display perturbed T cell development and function (19). In accordance with the distinct 
hematopoietic phenotypes of G.fil and G.fil B deficiency, normal adult animals express 
these two factors in a tissue-specific manner (10). G.fil is predominantly expressed in 
thymus, the site of T cell development, while G.fil B is expressed in spleen. Both factors 
are expressed in bone marrow (10). 
The unique physiological functions of G.fil and G.fil B may seem somewhat 
surprising given the similarities oftheir defined biochemical and oncogenic 
75 
functions (9;10). GFIl and GFIlB are two members ofa family of zinc-finger 
transcriptional repressors that are characterized by the presence of the SNAG (found in 
the Snail and Gfi 1 family of proteins) repression domain (9). Transcriptional repression 
by both GFIl and GFIlB requires an intact SNAG domain. Specifically, in in vitro 
transient transcription assays, SNAG activity can be abrogated by mutation of the Proline 
at position 2 to Alanine (P2A) (9). Furthermore, GFIl and GFIlB have been shown to 
bind very similar consensus DNA sequences, both of which have an absolute requirement 
for the tetranucleotide sequence AATC (10). Mutation of this AATC core to GGTC 
results in a lack of DNA binding in vitro (15). Despite the extensive similarities of these 
proteins, each contains a region unique in amino acid sequence, the activities of which 
are yet to be defined. 
We and others have reported that in T cells, transgenic expression ofGFIl causes 
an increase in the response to TCR-stimulated activation (19-21). Conversely, we have 
shown that GFIlB is induced during T lymphopoiesis at stages involving activation, and 
that transgenic expression of GFIl B in T cells leads to decreased activation (19). These 
effects were seen in both mature T cells in vitro and in thymocytes in vivo. While GFIlB 
transgenic mice display normal thymic cellularity, they share with Gfil deficient mice the 
characteristic of peripheral T lymphopenia. In addition, GFIIB transgenics display 
thymic abnormalities, including a defect in the formation of CDS SP cells, which can be 
partially corrected by transgenic expression ofGFIl(19). Thus, some of the observed 
GFIl B-mediated effects on T lymphopoiesis may result from the disruption of normal 
functions ofGFIl (19). We therefore sought to determine the mechanism by which 
GFIl B interferes with GFIl activity. 
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Upon comparison of expression levels of the transgenic GFIl and GFIlB, we 
discovered that endogenous GFIl is not expressed at detectable levels in GFIlB 
transgenic thymocytes. Given the roles ofGFIl and GFIlB as transcriptional repressors, 
we hypothesized that transgenic GFIlB represses the transcription of endogenous Gjil. 
In this report, we show that mouse, rat, and human Gjil are repressed by both GFIl and 
GFIlB, and that this repression is both direct and dependent on the SNAG repressor 
domain in vitro and in vivo. In addition, we identify in vitro GFIl binding of consensus 
recognition sequences in regulatory regions of the Gjil gene, and suggest previously 
undefined sequence requirements for binding by GFIl in nuclear complexes. 
Furthermore, we provide evidence that GFIl autoregulation may be a cell-type-specific 
mechanism, occurring in primary T cells and a T cell line, but not in a myeloid lineage 
cell line. 
Materials and methods. 
Mice. The GFIl and GFIlB transgenic mice were previously described (19). P2A-GFIl 
transgenic mice were generated similarly by cloning the P2A-GFIl-mutant cDNA into 
the BamHI site of the TLC vector (32). All mice were housed in the Donald Baxter 
Barrier Facility at the University of Louisville and used in accordance with protocols 
approved by the U ofL Institutional Animal Care and Use Committee. 
Plasmids. Plasmids used in transient transcription assays were previously described (9). 
Plasmids for in vitro transcription and translation were generated by cloning rat Gjil, 
LlZn4Gjil, or mouse Gjil B into the pcDNA3 vector (Invitrogen). Retroviral vector 
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expression constructs were generated by cloning triple Flag-epitope-tagged GFIl and 
mutant GFIl (SV40swap) (9) into the MIEV vector (63). 
Transfections, transduction, and transcription assays. For stable transfections, lurkat 
cells were electroporated as previously described (9). TLC transgene constructs encoding 
GFIl or GFIlB were co-transfected with empty pcDNA3.1 vector DNA at a ratio of22:1. 
Transfected cells were selected in the presence of ImglmL Geneticin (Invitrogen) and 
cloned by limiting dilution. 
293T cells were maintained in Dulbecco's Modified Eagle's Medium (DMEM) 
with 10% FBS, 1 % L-Gln, 1 % PenlStrep (Invitrogen). Cells were transfected with 
Lipofectamine 2000 (Invitrogen) according to the manufacturer's protocol using Opti-
MEM low serum medium (Invitrogen) and 2.5 x 105 cells/well in 24-well plates that were 
pre-coated with poly-L-Lysine (0.1 mg/mL, Sigma). Transfections were performed in 
triplicate. CAT assays were performed as previously described (9). A 2-tailed Student's 
T test determined P values. 
F or transduction experiments, Phoenix cells (64) were transiently transfected with 
retroviral constructs using calcium phosphate (Ca3(P04)2) (65) then co-cultured with 
U937 cells overnight. The transduced U937 cells were expanded and sorted on a 
F ACSV antage (BD); sorted GFP+ cells were analyzed after two weeks in culture. 
Northern and Western blot. For Northern blots, total RNA was extracted using 
Ultraspec RNA Isolation Solution (Biotecx Laboratories, Inc. Houston, TX) according to 
the manufacturer's protocol, and poly-A+ RNA was obtained using Oligotex Direct 
mRNA purification protocol (Qiagen Inc., Valencia, CA). Total RNA (20llg) or Poly A+ 
RNA (5Jlg) was electrophoresed in a 1 % agarose-formaldehyde gel and transferred to 
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MagnaGraph nylon membrane (Micron Separations, Inc., Westboro, MA). Membranes 
were probed in UltraHyb solution (Ambion, Austin, TX) according to the manufacturer's 
protocol. Radioactive probes were generated by Prime-I-Gene random priming kit 
(Promega, Madison, WI). 
Western blot detection ofGFIl and GFIlB was performed as previously 
described (19). Nuclear extracts ofU937 cells were made using NE-PER (Pierce) 
according to manufacturer's instruction, and protein concentration was determined using 
BCA Protein Assay Reagent (Pierce). Primary antibody was either a commercially 
available antiserum to the last 20 amino acids of GFIl (Santa Cruz, sc-6357), anti-Flag-
HRP (Sigma), or a mouse monoclonal to GFIl (2.5D.17). 
RNase and DNase. For resolution of the sequence of the rat locus, primer extension was 
performed with an end-labeled oligonucleotide complementary to exon I sequence, 
hybridized to 50llg total RNA from rat Nb-2lymphoma cells or normal rat thymus, and 
the reaction products were analyzed by electrophoresis through a 7% polyacrylamidel7M 
urea sequencing gel. 
To characterize the exon-intron boundaries and genomic organization of Gfil, an 
F344 rat genomic AD ash clone (8) was digested with EcoRI and the resulting fragments 
subcloned in pBluescript SK (Stratagene, Valencia, CA). Next, oligonucleotide primers 
based on the Gfil cDNA sequence were used to probe Southern blots of the genomic 
subclones, for PCR amplification, and for sequencing. 
Cultures were harvested, and nuclei were isolated and subjected to incremental 
DNase I digestions as previously described (66). 
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Electrophoretic mobility shift assays (EMSA). Shifts were performed essentially as 
described (14). In vitro transcription and translation (IVT) was performed using TNT 
T7-coupled reticulocyte lysate system (Promega) according to the manufacturer's 
protocol. Jurkat nuclear extracts (NE) were prepared using a standard Dignam protocol 
(67). The sense sequence of the -705 probe is 5'-
GGAGCAAACCTCAGGGATTGGGTGTCAAGGTA-3', and the mutant probe is 5'-
GGAGCAAACCTCAGGGACCGGGTGTCAAGGTA-3'. The underlined bases were 
added for labeling using Klenow (NEB) and a)2P-dCTP (Amersham, Piscataway, NJ). 
NE (2.5 ug) or IVT protein (3 to 5 uL) was pre-incubated in binding buffer (14) at room 
temperature for 20 minutes, with cold oligonucleotide or antibodies [anti-GFIl (sc-8558) 
or normal goat antiserum (sc-2028)] for competition and super-shift assays. Labeled 
probe (50,000 cpm) was added, and the reaction continued at room temperature for 30 
minutes. Samples were electrophoresed through a 6% non-denaturing polyacrylamide 
gel, which was dried and exposed to film. 
ChIP. ChIP assays were performed as previously described (13). Each experiment was 
performed twice with similar results, and representative data are shown. 
Results. 
Endogenous murine Gftl is repressed by transgenic expression of GFIl or GFIlB in 
primary thymocytes. 
Transgenic expression of GFIlB engenders defects in T lymphopoiesis, some of 
which can be rescued by simultaneous forced expression of GFIl (19). Because GFIl 
and GFIlB have nearly identical DNA binding domains (10), we reasoned that GFIlB 
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may alter T lymphopoiesis by competing with endogenous GFIl for DNA binding on 
specific promoters. However, Western blot analysis of whole celllysates from GFIlB-
transgenic thymocytes revealed undetectable levels ofGFIl protein (Figure 16A). These 
results led us to investigate the levels of endogenous Gfil transcript in GFIl and GFIl B-
transgenic thymocytes. Since the transgenes lack the Gfil 3' untranslated region, we 
performed Northern analysis with a murine Gfil 3' -untranslated-region probe on poly-
A+-selected RNA from GFIlB-transgenic thymi. These analyses revealed a dramatic 
reduction in the level of endogenous Gfil transcript (Figure 16B). Moreover, transgenic 
mice with forced low-level expression of GFIl display a mild reduction of endogenous 
Gfil message (Figure 16B). Therefore, GFIlB-transgenic T cells are essentially devoid 
ofGFIl, and Gfil may be targeted for repression by both GFIl and GFIlB. 
The SNAG-repression-domain mutant P2A-GFIl profoundly de-represses 
endogenous murine Gfil. 
The P2A-GFIl mutation significantly impairs GFIl-mediated repression (9). 
Therefore, we predicted that the P2A-GFIl mutant would act as a dominant-negative and 
interfere with GFIl function. We constructed transgenic mice in which P2A-GFIl is 
expressed in T cells through the Lck proximal promoter and a CD2 enhancer (Figure 
16C) (32). Deletion of Gfilleads to a significant decrease in thymocyte numbers and 
impairs T lymphopoiesis (11;16;17). However, contrary to our expectation of dominant-
negative GFIl activity by the P2A-GFIl mutant, thymi ofP2A-GFIl-transgenic mice 
display no discernable phenotype (data not shown). Northern analysis ofthymus RNA 
with a transgene-vector-specific probe revealed adequate expression of P2A-Gfil 
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Figure 16. Endogenous murine Gfil is repressed by GFIl and GFIlB in 
thymocytes. A. Western blot analysis of protein (75 ug) from thymocyte whole cell 
lysates of two wild type (WT) and two GFIlB transgenic mice. The blots were probed 
with an antibody against the last 20 amino acids of GFIl that is cross-reactive to GFIlB 
(sc-6375). A loading control (IRFl) is shown. B. Northern blot analysis ofpoly-A+ 
RNA (5 Jlg). Endogenous Gfil was detected using a probe specific to the 3' untranslated 
region of mouse Gfil. Blots were stripped and probed with a loading control (MDM2). 
Note: These data were generated by Dr. H. Leighton Grimes and Loretta Doan. C. 
Diagram of the transgene construct used in creating P2A-GFIl transgenic mice. The 
transgene vector(32) is identical to that utilized to create GFIl and GFIlB transgenic 
animals. D. Northern blot analysis of total RNA (20 ug) from thymocytes of two wild 
type (WT) and two P2A-GFIl (P2A) transgenic mice using the same probe as in B. 
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message (data not shown). We subsequently performed Northern analysis ofP2A-
transgenic thymocytes with the murine Gfil 3' untranslated region probe. This analysis 
revealed a striking de-repression of endogenous Gfil in the presence oftransgenic P2A-
GFIl (Figure 16D). Whereas in normal thymocyte RNA the detection of Gfil requires 
poly-A+ selection (Figure 16B), the Gfil signal in P2A-transgenic thymocyte RNA was 
easily detected by Northern blot analysis of 20 Jlg of total RNA (Figure 16D). The 
profound de-repression of endogenous Gfil in repression-defective P2A-GFIl-transgenic 
thymocytes is evidence for direct autoregulation of Gfil. 
Identification of the rat Gft1 promoter. 
Given the probability of direct repression of Gfil, we next wanted to examine the 
Gfil promoter for GFIl/GFIlB DNA-binding sites. However, the sequence of the Gfil 
promoter had not been well resolved. Early identification of Gfil as an oncogene was 
performed in rat T cell leukemia lines, providing a biological impetus for studying the 
transcriptional regulation of rat Gfil. Genomic clones from the rat locus were analyzed 
by restriction endonuclease digestion, followed by Southern blotting with Gfil cDNA 
probes and sequencing. We determined both the exonlintron boundaries of the gene 
(Figure 17A), and the organization of the rat Gfillocus (Figure 17B). Specifically, 
examination of the sequence of intronl exon boundaries revealed the presence of 7 exons 
and 6 introns. The exonlintron boundary sequences are homologous to the previously 
published mouse locus (68), with minor exceptions. The genomic organization of rat 
Gfil is diagramed in Figure 17B and spans 9.5 kb of sequence. These data were 
corroborated by the recently available rat genomic sequence in GenBank (data not 
shown). 
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Figure 17. Characterization of rat Gfillocus and identification of the transcription 
start site. A. Exonlintron boundaries of rat Gfil. Shown are the splice donor and 
acceptor sites as determined by sequencing. B. Schematic representation of the 
organization of the rat Gfillocus. Exons 1-7 are depicted as gray boxes. Arrows identify 
DNase hypersensitive sites, with the longest arrow representing the start site of 
transcription. Roman numerals indicate probes used for DNase hypersensitivity analysis. 
C. Southern blot analysis of DNase hypersensitivity assays. Nuclei from Nb2 (lanes 1-4 
ofleft panel), A2 (lanes 5-8 ofleft panel), or LE3Spi (right panel) rat cell lines were 
digested with increasing concentrations of DNAse I, the DNA was digested with HindIII 
restriction endonuclease, and Southern blots were hybridized with probes I and II. 
AI HindlII molecular weight markers are indicated on the left of each blot. The arrow 
indicates the major site of hypersensitivity, corresponding to the longest arrow in panel 
B. Minor bands represent other regions of putative transcriptional control corresponding 
to smaller arrows in panel B. D. RNase protection assay identifies the start site of 
transcription. The left panel shows representative results of RNase protection analysis 
from rat Nb-2lymphoma cells (1) and normal rat thymus (2). Arrows indicate the major 
protected fragments and the corresponding nucleotides on a sequencing gel. The right 
panel depicts the sequence of the start site and the consensus sequence of an Inr. Note: 
All of these data were generated by Dr. C. Blake Gilks and Dr. Susan D. Porter 
(Department of Pathology and Genetic Pathology Evaluation Centre, Vancouver General 
Hospital and the University of British Columbia). 
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To determine potential regulatory regions, DNase hypersensitivity assays were 
performed (Figure 17C). Analysis of rat Nb2 and A2 lymphoma cells using a genomic 
probe (Figure 17B, I) revealed hypersensitive sites clustering around exon 1 (arrows in 
Figure l7B). Many of these sites occur within the first intron, but the major site of 
DNase hypersensitivity is just upstream of the first exon (longer arrow Figure l7B, and 
arrow Figure 17C). In LE3Spi cells, two downstream hypersensitive sites were also 
identified using probe II and are indicated in Figure 17B. The same pattern was seen 
with both probes with or without prolactin addition to prolactin-dependent Nb2 cells, and 
with or without Interleukin-2 addition to the Interleukin-2-dependent LE3Spi cell line 
(data not shown). 
We next mapped the start site of transcription of the rat Gfil gene. The mouse 
Gfillocus has both a major transcription start site 5' of exon la, and a minor one in the 
first intron (68). Therefore, we performed RNase protection analysis to locate the 
transcriptional start site(s) in the rat Gfil gene. In RNA from rat Nb2lymphoma cells, a 
sequence proximal to exon 1 was identified as the single start site of transcription in the 
rat Gfil gene (Figure l7D). This sequence (TCAGAGC, Figure l7D) corresponds to the 
consensus sequence of an initiator element (Inr) (69). Inr elements are commonly 
utilized as transcription start sites in TATA-less lymphoid-specific genes such as TdT 
(70). In agreement with this, we found no evidence of a canonical TAT A box in the 
sequence of this region. Moreover, the relative position of the Inr corresponds to the 
major site of DNase I hypersensitivity. In contrast to both mouse and human Gfil which 
generate mUltiple sized transcripts, the rat locus generates a single transcript (8). No start 
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sites were detected in the first intron of the rat gene (data not shown). Thus, the Oftl rat 
locus appears to have a single start site corresponding to a consensus Inr sequence. 
Mouse and human Gfilloci contain sequences homologous to the rat Gfil promoter 
including conserved GFIl binding sites. 
The sequence around the transcription start site of the rat Oftllocus was 
compared to the sequences of the mouse and human Oftlloci. This analysis revealed a 
great deal of homology among rat, mouse and human sequences up to 808 bp upstream of 
the putative Inr of the rat locus (Figure 18A, gray areas). This amount of sequence 
homology is unusual for non-coding DNA, emphasizing the probable importance of this 
region in the transcriptional control of Oftl. 
The Inr sequence is conserved in the mouse locus, but not in the human sequences 
we identify here. However, the homologous region we show is defined as intron 1 of the 
human gene (71). Human Oftl is reported to have more than one transcription start site, 
and the major start site of the human Oftl promoter (72) contains a consensus Inr element 
by our analysis (data not shown). 
Since Oftl is repressed in GFIl and GFIlB transgenic thymocytes, we next 
examined the sequence for GFIl/GFIlB binding sites by using a matrix similarity 
program (73). Putative GFIl/GFIlB binding sites that are conserved among all three 
species are annotated and underlined, as is the rodent Inr (Figure 18A). Furthermore, 
alignment of the first intron of the rat locus revealed extensive homology and two 
additional potential GFIl/GFIlB binding sites that are also conserved in all three species 
(data not shown). 
GFIl and GFIlB repression is conserved in the rat Gfil promoter. 
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Figure 18. The rat Gfil promoter is highly homologous to mouse and human loci, 
and is sensitive to repression by GFIl and GFIlB. A. Sequence alignment of mouse 
and human Gfilloci to the rat Gfil promoter. Regions in gray represent areas of identity 
among all three species. GFIl binding sites and the lnr are underlined and annotated. 
Numbering is according to the rat sequence with +1 as the first nucleotide in the putative 
lnr. B. The Gfil-promoter CAT reporter was cotransfected into 293T cells with CMV5 
expression vector, or CMV5 expression plasmids encoding GFIl, GFIlB, or the 
repression-mutant P2A-GFIl. Transfection efficiency was controlled by cotransfection 
of a B-galactosidase expression construct. Relative CAT activity was derived by 
normalization to B-galactosidase levels within individual transfections. The plot 
represents the averaged normalized CAT activity ± SEM from triplicate transfections. 
Similar results were obtained in three independent experiments. C. The VPI6-Zn 
mutant encodes the transcriptional activation domain ofVP16 fused to the DNA-binding 
Zn fingers ofGFIlB. VPI6-Zn activates transcription ofGFIl/GFIlB target genes (10). 
The Gfil-promoter CAT reporter was cotransfected with CMV5 expression vector, or 
CMV5 expression plasmids encoding VPI6-Zn. Normalization was performed as in A. 
Fold activation was derived by dividing the normalized CAT activity in the presence of 
VPI6-Zn to CMV5 vector controls. 
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We next created a rat Gfi-promoter-reporter construct containing the sequence 
from -808 bp 5' of the transcription start site to exon 2. This sequence contains all of the 
DNase hypersensitive sites identified in the promoter region and first intron. Moreover, 
this region is highly conserved between mouse, rat and human Gfilloci. Transfection of 
several truncations of this construct into two different GFIl expressing cell lines resulted 
in significant increases in reporter activity upon removal of the region between -808 and -
245 (data not shown). Therefore, a negative regulatory element is present in the GFIl 
promoter. 
293T cells are transformed kidney epithelial cells that express a low level of GFIl 
(data not shown), and were used for transient transcription assays. As shown in Figure 
18B, co-transfection ofa Gfil promoter-driven CAT reporter construct and CMV5 
expression constructs encoding GFIl or GFIlB resulted in decreased reporter activity in 
comparison to empty CMV5 vector (P = 0.006, and P = 0.002 respectively). However, 
co-transfection of the repression-defective P2A-GFIl has no effect on reporter activity 
(Figure 18B). While these data provide the expected result that GFIl and GFIlB can 
repress the Gfil promoter and that the repression observed is mediated by the SNAG 
domain, they do not recapitulate the potent de-repression of the Gfil promoter as seen in 
P2A-GFIl transgenic thymocytes. We consider that 293T cells may not express enough 
endogenous GFIl to effectively repress multiple copies of the transfected reporter 
construct, and that transient transcription assays do not reproduce all aspects of 
chromatin-regulated gene expression. 
To examine whether the repression of the rat Gfil promoter is due to direct 
binding of GFIl to the promoter region, we utilized an expression construct encoding the 
91 
activation domain of the herpes simplex virus VP16 protein fused to the zinc fingers of 
GFIlB (VPI6-Zn) (10). This construct encodes a transcriptional activator with the DNA-
binding specificity ofGFIl/GFIlB. Co-transfection of the GjiJ-CAT reporter with the 
VPI6-Zn expression vector resulted in a dose-dependent increase in CAT activity (Figure 
18C), suggesting that the observed repression by GFIl and GFIlB is a result of direct 
binding ofthe promoter by GFIl and GFIlB. The high frequency of conserved putative 
GFIl/GFIlB binding sites, along with the observed GFIl- and GFIlB-mediated 
repression of both endogenous GjiJ in transgenic mice and rat GjiJ promoter-reporter 
constructs, indicate that GjiJ is a direct target ofGFIl and GFIlB transcriptional 
repression in mice and rats. 
Human Gfil is repressed upon forced expression of GFIl or GFIlB. 
To determine ifhuman GjiJ is also responsive to GFIl and/or GFIlB, we 
transfected a human T cell line, lurkat, with a selectable marker and the Lck-CD2-GFIl 
and -GFIlB constructs and selected stable clones. Western blot analysis revealed varying 
expression levels ofGFIlB (Figure 19A, clones IB.l and IB.2), and high levels ofGFIl 
(Figure 19B, clones 1.1 and 1.2). Northern blot analysis of poly-A + selected RNA 
(Figure 19C) with a human GjiJ-specific probe revealed that forced expression ofGFIl 
or GFIlB resulted in repression of endogenous human GjiJ in lurkat T cells. 
Furthermore, the repression by GFIIB is dose-dependent in that the clone expressing 
higher levels ofGFIlB has lower steady state levels of GjiJ RNA (compare Figure 19A 
and Figure 19C, clone 1 B.l versus 1 B.2). In contrast to the mild repression of GjiJ in 
low-level-expressing GFIl transgenic mice (Figure 16B), high levels of GFIl result in a 
dramatic decrease in steady state levels of GjiJ mRNA in lurkat T cells (compare Figure 
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Figure 19. GFIl and GFIlB repress endogenous human Gfil in the Jurkat T -ALL 
cell line. A and B. Western blot analysis ofGFIlB (A, IB.1 and IB.2) and GFIl (B, 1.1 
and 1.2) in independent stably transfected and selected Jurkat clones. Blots in A and B 
were probed with the same antisera as in Figure 16. C. Northern blot analysis of poly-
A + RNA (5 ug) from Jurkat clones using a probe specific for human Gfil. Ethidium 
bromide staining of the poly-A + RNA is shown for equal loading. Similar results were 
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19B and Figure 19C, clones 1.1 and 1.2). Therefore the regulation of GjiJ by GFIl and 
GFIl B is conserved among mice, rats and humans. 
Jurkat nuclear extract can form in vitro proteinlDNA complexes with putative GFIl 
binding sites in the rat Gfil promoter and intron. 
The GFIl consensus binding site has been defined by in vitro studies as 
TAAATCAC(AlT)GCA, with an absolute requirement for the AATC core (10;15). To 
determine which of the putative sites in the GjiJ promoter bind to endogenous GFIl, we 
designed 30-bp oligonucleotide probes for use in electrophoretic mobility shift assay 
(EMSA) with Jurkat nuclear extracts. We observed several different proteinIDNA 
complexes, some of which were unique to individual probes, and most of which were 
relatively minor in intensity. However, one of the probes (GRP2), corresponding to a 
putative GFIl binding site at -705 (rat AATC core relative to Inr), was strongly shifted in 
a doublet with greatly retarded mobility (Figure 20). Another probe (GRP4), containing 
two putative binding sites located at -434 and -421, shifted with the same pattern, but at a 
much lower intensity. In order to begin to discern whether any observed binding may 
suggest functionality, we engineered a probe to contain a GFIl binding site that has been 
shown to be active in transient transcription assays (B30GRP; (9)). This probe contained 
the B30 binding site and flanking sequence from a putative binding site located at -558 in 
the rat promoter, and was named B30GRP. This probe shifted in the same doublet 
pattern as did GRP2 and GRP4; however, the intensity of the shifted band was 
significantly less than that observed for either endogenous promoter sequence. Complex 
formation was competed away by adding excess cold oligonucleotide (Figure 20). 
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Figure 20. Formation of protein-DNA complexes with Jurkat nuclear extract and 
oligouncleotide probes containing GFIl consensus binding sites in rat Gfil promoter 
sequence. A. Of seven oligonucleotide probes containing a total of eight predicted GFIl 
recognition sites (GRP4 has two sites) in the rat Gfil proximal promoter, only GRP2 (-
705) and GRP4 (-434 and -421) display appreciable binding to proteins in Jurkat nuclear 
extract. Migration of the complexes formed with these two probes is identical to the 
migration of complexes formed between Jurkat nuclear extract and a synthetic consensus 
GFIl binding site (B30GRP). Note: These data were generated by Morgan Jeffries 
under the direction of Loretta Doan. B. A probe containing two putative GFIl binding 
sites located in the intron of the rat and mouse genes (GRI) also forms these complexes 
when incubated with Jurkat nuclear extract. C. The sequence of the rat promoter with 
the locations of the probes indicated. Each probe sequence is underlined, and the AA TC 
core of each putative GFIl binding site is in bold. The italicized nucleotide is contained 
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Further examination of potential regulatory elements in the rat intron revealed two 
putative GFIl binding sites that are conserved in the mouse intron (data not shown). 
These sites lie close together and are both contained in the probe GR!. Figure 20 shows 
that this probe shifts in a doublet pattern identical to that observed with the promoter-
based probes, and that this binding can be competed by the addition of excess cold probe. 
GFIl binds directly to a predicted GFIl binding site in the rat Gfil promoter. 
To determine whether GFIl is present in, and required for, the complexes 
observed in the doublet, we more closely examined the properties of complexes formed 
between Jurkat nuclear extract and GRP2. Pre-incubation of Jurkat nuclear extract with 
antiserum against GFIl disrupted the complexes (Figure 21A); no effect was noted using 
a control antiserum. Additionally, as observed in Figure 20, complex formation was 
efficiently competed in the presence of excess cold wild-type probe, but not in the 
presence of excess cold mutant probe (AA TC->GGTC). Finally, when the mutant probe 
was labeled and incubated with Jurkat nuclear extract, the doublet was not detected. 
Combined, these EMSA results demonstrate that complex formation on the -705 
oligonucleotide requires both GFIl and the Ofi] recognition sequence, strongly 
suggesting that GFIl is binding directly to this site. Similar results were obtained with 
other potential binding sites for GFIl (data not shown). 
To ensure that GFIl and GFIlB are capable of binding to the -705 site, we 
performed EMSA with in vitro transcribed and translated (IVT) proteins. As published 
by others (14), we note that IVT mouse GFIlB results in two proteins (Figure 2IB). IVT 
GFIl and GFIlB shifted the -705 oligonucleotide in EMSA (Figure 2IC), and two 
protein-DNA complexes are seen in the presence of the two GFIlB products. GFIl 
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Figure 21. GFIl and GFIlB bind in vitro to a conserved site in the rat Gfil 
promoter. A. EMSA analysis of GFIl binding to the conserved site at -705 bp. Jurkat 
nuclear extract incubated with the -705 bp probe alone (lane 2) forms several distinct 
protein-DNA complexes. Supershift analysis was performed with a goat polyclonal 
antibody to GFIl (lane 3). Pre-immune goat sera served as control (lane 4). Cold 
competition was performed with a 30-fold excess of cold probe (lane 5), or cold mutant 
probe (AATC to GGTC) (lane 6). Incubation of Jurkat nuclear extract with a labeled 
mutant probe (lane 6). W = wild type probe, M = mutant probe, G = goat anti-GFIl 
antiserum, Cg = control goat antiserum. B. In vitro transcribed and translated GFIl, 
GFIlB, or a mutant ofGFIllacking the fourth zinc finger (~Zn4) were 35S labeled, run 
on a denaturing polyacrylamide gel, and subjected to autoradiography. Representative 
autoradiographs are shown. C. IVT GFII and GFIlB, but not ~Zn4 GFIl, form 
complexes with the -705 oligonucleotide probe. Note: These data were generated by 
Morgan Jeffries under the direction of Loretta Doan. 
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requires zinc fingers 3, 4, and 5 for sequence-specific DNA binding (15). As expected, 
EMSA using a mutant of GFIl lacking zinc finger 4 (~n4; Figure 21 C) did not result in 
retarded mobility ofGRP2. These data support the suggestion that GFIl in Jurkat 
nuclear extract is binding directly to these identified sites. Furthermore, the relatively 
faster mobility of the complex formed between DNA and IVT GFIl, as compared to the 
mobilities of the two bands in the doublet observed with Jurkat nuclear extract, suggests 
that in nuclear extract, GFIl exists in complexes with other proteins. 
Potential differences in DNA sequence requirements for binding by GFIl in nuclear 
complexes. 
The GFIl consensus site was defined by using synthetic oligonucleotides and 
bacterially synthesized proteins encoding GST fused to GFIl (15). This sequence is 
utilized by the matrix homology program MatInspector (73) to identify putative GFIl 
binding sites in the promoters of user-defined genes. When MatInspector identifies 
putative recognition sequences, it also assigns a percent consensus score to the sites in 
question. We limited our analyses to sites that had a 90% or greater score. We expected 
those sites with the highest scores to show the most efficient binding to GFIl. However, 
the relative binding differences we observed in our EMSA analysis using Jurkat nuclear 
extract as a source for GFIl did not agree with the predicted affinities. Due to the limited 
number of oligonucleotide probes (eight), our initial examination failed to identify a 
common sequence requirement among those that bound GFIl when compared to those 
that did not. However, upon further examination of the promoter sequence, and 
comparison to the public domain sequences that became available during the course of 
this work, we discovered seemingly minor discrepancies in the sequences of both GRP2 
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and GRP4. (The other sequences used in probes of putative binding sites were verified as 
accurate by the same analyses.) Specifically, the apparently correct sequence of GRP2 
has an A at the position +6 from the first A of the AA TC core (instead of the T in our 
original probe), while GRP4 contains a T at position -2 (instead of the C in our original 
probe) (Figure 22A). We predicted that neither change in sequence would alter binding 
by GFIl because, in the in vitro experiments that first defined the GFIl consensus 
sequence, both nucleotides were selected in approximately the same number of 
oligonucleotides in each case (15). To test this prediction, we re-synthesized the 
oligonucleotide probes with the correct sequence and performed EMSA to compare GFIl 
binding. 
As seen in Figure 22B, the T to A change in the sequence of GRP2 affected 
neither the pattern nor the intensity of complex formation (compare GRP2 and GRP2.2). 
However, the C to T alteration of the first site in GRP4 drastically changed the pattern of 
complex formation (compare GRP4 and GRP4.2). GRP4.2 shifts in a single complex 
with a somewhat faster mobility than the lower band in the doublet observed with GRP2, 
GRP2.2, and GRP4. Competition assays defined this first site as being solely responsible 
for the observed GFIl binding in both GRP4 probes (data not shown). This suggests that 
there are several GFIl-containing complexes in lurkat nuclear extract, and that changing 
the nucleotide at -2 from C to T alters the ability of these complexes to bind. Similar 
results were obtained when nuclear extract from Nb2 cells were used as the source of 
GFIl (data not shown). While suggestive, these data are certainly not conclusive, and 
this hypothesis remains to be tested. 
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Figure 22. Jurkat T cell nuclear extracts contain multiple GFIl complexes with 
specific DNA sequence requirements and varying DNA binding affinities. A. 
Sequence alignment of oligonucleotide probes. The sequences of the original probes are 
indicated as GRP2, GRP4, GRI, and B30GRP. Probe GRP2 contains the site at -705, and 
probe GRP4 contains two binding sites at positions -434 and -421. Probe B30GRP is a 
consensus GFIl binding site with flanking sequence from the Gfil rat promoter that 
surrounds a putative binding site at -558. The ultimately resolved sequences of the rat 
promoter are indicated as GRP2.2 and GRP4.2. The changed nucleotides are shown in 
bold. B. GRP2, GRP2.2, and GRP4 show the same binding pattern, but GRP4.2 forms a 
single complex with greater mobility than either of those formed with the other three 
probes. C. Cross-competition confirms the relative binding affinities of oligonucleotide 
probes (Figure 20). GRP2.2 was radiolabeled and used as probe (lane 1, probe only; lane 
2, probe with 1urkat nuclear extract). Competition analysis was performed using 
increasing molar amounts (1 OX, 25X, and 50X the ng quantity of probe) of GRP2.2 
(lanes 3-5), GRP4.2 (lanes 6-8), GRI (lanes 9-11), mutlGRI (the first AATC mutated to 
GGTC; lanes 12-14), mut2GRI (the second AATC mutated to GGTC; lanes 15-17), and 
mut3GRI (both AATC mutated to GGTC; lanes 18-20). GRP2.2, GRI, and mut2GRI all 
compete with GRP2.2 for binding to GFIl in 1urkat nuclear extract. GRP4.2, mutl GRI, 
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To ensure that the observed differences in intensities of the complexes are a result 
of the relative strength of binding by GFIl and not due to artifact such as poor probe 
labeling, we performed cross-competition analysis (Figure 22C). In this assay, GRP2.2 
was used as radio labeled probe, and competition was performed using different unlabeled 
oligonucleotides. This analysis showed that the corrected site at -421 (GRP4.2) does not 
compete away the binding to the site at -705 (GRP2.2). Furthermore, it confirmed that 
the affinity for GFIl binding to GRP2 is greater than that for binding to the intronic sites 
(GRI), as GRI does not effectively compete for binding unless added in 25 or 50 fold 
excess, whereas GRP2.2 completely competes its own binding at 10 fold excess. The 
reverse experiment was also done, in which GRP2.2 effectively competes all binding by 
GRI when added in 10 fold excess (data not shown). In addition, analysis of the AA TC 
to GGTC mutants of each of the putative binding sites in GRI reveals that the first site is 
solely responsible for competition; when this site is mutated, GRI is unable to compete 
with GRP2 even at 50 fold excess (compare lanes 9-11 and 12-14). However, mutation 
of the other intronic site did not affect competition (compare lanes 9-11 and 15-17). 
Therefore, the first of the two predicted GFIl binding sites in the intron is bound by 
GFIl, whereas the second is not. Furthermore, the site at -705 binds more GFIl complex 
than does any other GFIl binding site identified in our in silico analyses. 
GFIl autoregulation is not observed in a myeloid lineage cell line. 
Both Gjirl - mice and Gjil-mutant humans display profound neutropenia 
(12; 16; 17), indicating a role for GFI1 in myeloid differentiation. U937 is a bi-potential 
human myeloid-precursor cell line that can differentiate into monocytes or neutrophils 
(74). U937 cells express GFIl (13). To determine if GjiJ autoregulation is active in non-
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Figure 23. GFIl autoregulation occurs in T cells but not in a myeloid-lineage cell 
line. A. Western blot analysis of human U937 cells transduced with retroviruses 
encoding Flag-tagged GFIl with an anti-Flag antibody (top) or anti-GFIl antibody 
(bottom). Note: These data were generated by Dr. Christopher M. Jay. B. Northern blot 
analysis of endogenous Gfil transcripts using a probe specific to the human Gfil 3' 
untranslated region. C - F. Chromatin immunoprecipitation analysis of wild type Jurkat 
T cells or U937 cells using either rabbit or goat polyclonal antisera to GFIl (aGFIl Ab). 
Non-specific rabbit and goat sera served as control (control Ab). Primers for the 
amplification reactions targeted the promoter or 3' untranslated region of human Gfil. 
Input = 0.005 to 0.01 % of input chromatin. J = Jurkat. U = U937. P = promoter. 3' = 3' 
region of Gfil. R = rabbit polyclonal antiserum G = goat polyclonal antiserum. Note: 
These data were generated by Zijun Duan and Marshall Horwitz (Department of 
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lymphoid lineages we transduced U937 cells with retroviral vectors encoding Flag-
epitope-tagged GFIl (Figure 23A, U1.1 and U1.2). This Flag-tagged GFIl was 
confirmed to be an active transcriptional repressor in transient transcription assays (data 
not shown). The transduced U937 cells express the epitope-tagged GFIl and have higher 
levels of GFIl overall (Figure 23A); in fact, the level of expression was similar to that 
observed in the stably transfected Jurkat T cells (compare Figure 19B with Figure 23A). 
However, we did not observe profound repression of the endogenous Gfillocus in U937 
cells (Figure 23B). While there appears to be a mild reduction in the expression of 
endogenous Gfil, it does not compare with the repression observed in Jurkat T cells. We 
therefore conclude that, unlike T lymphocytes, U937 myeloid cells do not display 
effective Gfil autoregulation. 
GFIl binds the Gft] promoter in live T cells. 
To determine the biological relevance of Gfil autoregulation, we performed 
chromatin immunoprecipitation (ChiP) analysis of cross-linked protein-DNA complexes 
from Jurkat T cells. This technique reveals protein-DNA interactions within the context 
of living cells. Amplification using primers that flank the -705 GFIl binding site resulted 
in a PCR product from chromatin immunoprecipitated with rabbit antisera to GFIl, but 
not when immunoprecipitation was performed using control antisera (Figure 23C). 
Essentially the same result was found with goat antisera to GFIl and control goat antisera 
(Figure 23D). In contrast, using the same analysis, we were unable to amplify a product 
using primers to a 3' region of Gfil (that does not contain GFIl binding sites by our 
analyses) (Figure 23E). Thus, the ChiP result is specific to the promoter region of Gfil. 
While the ChiP analysis does not prove that GFIl is specifically bound to the -705 site, 
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these in vivo data show that GFIl does bind its own promoter in living T cells. 
Moreover, these data suggest that the Gfil autoregulation we observe is indeed a 
physiologically relevant cellular mechanism. 
GFIl does not bind the Gfil promoter in living myeloid cells. 
We repeated ChIP analysis with the U937 cell line. In contrast to our results with 
lurkat cells, we did not find GFIl bound to the Gfil promoter in U937 cells (Figure 23F). 
These data provide a potential reason for the lack of repression observed in Figure 23B. 
GFIl in U937 cells is capable of DNA binding, as we have published the binding ofGFIl 
to a number of promoters in this cell line (13). Furthermore, the general chromatin 
environment of the Gfillocus is permissive for DNA binding, as U937 cells express 
endogenous GFIl (Figure 23A). It is of course possible that localized chromatin control 
may alter the promoter to make the GFIl binding sites inaccessible. In any case, the 
ChIP analyses indicate that GFIl autoregulation is not active in all cells that express Gfil, 
and may not occur in cells of myeloid lineage. 
Discussion 
GFIl is a transcriptional repressor protein that plays important biological roles in 
hematopoietic and neuronal cell development (11;16;17;75). Gfil was originally 
identified in an in vitro screen for genes that, upon deregulated expression, engender 
progression of T cell leukemias to Interleukin-2 independent growth (8). Transgenic 
overexpression of GFIl is poorly oncogenic, but potently collaborates with transgenic 
expression ofMYC or PIM oncoproteins to cause leukemia (76). In contrast, deletion of 
Gfilleads to profound lymphopenia (16;17). Since Gfil expression is critical for normal 
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hematopoiesis, and overcoming regulatory control of GjiJ accelerates oncogenesis, the 
transcriptional control of GjiJ is of great interest. Here we have shown that GFIl, and 
the closely related GFIlB, both repress the transcription of mouse, rat, and human GjiJ. 
We present several lines of evidence supporting a direct and physiologically 
relevant mechanism of GjiJ repression by GFIl. First, GFIl binding sites in the rat GjiJ 
promoter are conserved in the mouse and human GjiJ loci. Second, in primary 
thymocytes, transgenic expression of GFIl correlates with repression of endogenous 
GjiJ steady-state mRNA levels, whereas expression of a repression-defective GFIl 
mutant correlates with a profound de-repression of murine GjiJ. Third, in the human 
lurkat T cell line, forced overexpression of GFIl correlates with reduced endogenous 
GjiJ steady-state mRNA levels. Fourth, in EMSA analysis, in vitro transcribed/translated 
GFIl and endogenous GFIl-containing nuclear complexes bind sequences in the rat GjiJ 
promoter. Finally, ChIP analyses with two different antisera indicate that GFIl binds to 
its own promoter in living lurkat T cells. These in vitro and in vivo analyses provide 
strong support for the hypothesis that GFIl regulation of GjiJ is physiologically relevant. 
In fact, GjiJ autoregulation is evolutionarily conserved, as pag-3, the Caenorhabditis 
elegans ortholog of GjiJ, is autoregulated (77). 
GFIl and GFIlB control GjiJ expression. The abilities of GFIl and GFIlB to 
repress endogenous GjiJ seem comparable. Similar expression levels of the two factors 
in stably transfected lurkat T cells resulted in similar repression. Furthermore, co-
transfection of equal amounts ofGFIl and GFIlB expression plasmids with a GjiJ 
promoter-driven reporter resulted in nearly equal levels of repression. The regulation of 
Gjil by GFIlB is reciprocated. In addition to the data presented here, ChIP analysis in 
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KG-I, U937, and lurkat cells using antibodies against GFIl demonstrated that GFIl 
binds to the GfilB promoter region in living cells (13). Together, these data suggest 
cross-regulation of Gfil and GfilB. 
GFIl/GFIlB cross-regulation provides a potential explanation for differential 
steady-state expression of Gfil and GfilB, and suggests a molecular mechanism to ensure 
that the function of the properly expressed transcription factor is not blocked by aberrant 
expression of the other. We note that both factors can be simultaneously expressed (19). 
Specifically, Gfil and GfilB are co-expressed during specific stages ofT cell 
development coincident with activation (19). The repression of Gfil by GFIlB provides 
new insight into the transient expression of GFI 1 B in thymocytes that have been recently 
signaled for positive selection. Namely, GFIlB may be present to temporarily repress 
Gfil, thereby decreasing the potentiative effect of GFIl on TCR stimulation and fine-
tuning the cellular response to activation. Since GFIl increases T cell activation (19-21), 
GFIlB expression may indirectly inhibit T cell activation through the repression of Gfil. 
Mutation of GFIl in both mice and humans causes profound neutropenia 
(12;16;17). Since the primary function ofneutrophils is to defend against bacteria and 
fungal infection (78), humans with either Severe Congenital Neutropenia (SCN) or 
"nonimmune chronic idiopathic neutropenia of adults" (NI-CINA) are predisposed to 
opportunistic infections (79). We have recently shown that GFIl is mutated in SCN and 
NI-CINA patients without mutations in neutrophil elastase (ELA2) (12), the most 
prevalent mutation in SCN (79). In contrast to ELA2-mutant SCN patients, GFIl-mutant 
SCN patients are also mildly lymphopenic and have T cell activation defects (12). In 
mice, deletion of Gfil results in a profound neutropenia that is strikingly similar to that 
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seen in human GFIl-mutant SCN patients (16). However, the lymphoid phenotype of 
Gjirl - mice is dramatically worse than that ofGFIl-mutant SCN humans (16;17;17). 
Cell type specific Gjil autoregulation may explain the disparity between the 
lymphoid phenotype of Gjirl- mice and Gjil-mutant humans. Our T-cell specific P2A-
GFIl transgenic mice lack a Gjil-deleted phenotype and demonstrate significant de-
repression of the endogenous Gjil locus. Thus, by interfering with the transcriptional 
repression activity of endogenous GFIl, the P2A-GFIl mutant may induce compensation 
in T cells to prevent a complete loss of GFIl function. In fact, humans with SCN are 
heterozygous for mutant Gjil (12). In a manner similar to the P2A-GFIl transgenic 
mice, the expression of the mutant GFIl in SCN patient T cells might lead to de-
repression of the wild-type allele, providing compensatory expression of wild-type GFIl 
and sufficient GFIl activity in these cells. In contrast, myeloid progenitor cells, like the 
U937 myeloid lineage cell line, may not exhibit Gjil autoregulation. These cells would 
not have compensation by the wild-type allele and would effectively lose most or all 
GFIl function. Thus, cell-type specific Gjil autoregulation provides a potential 
explanation for the differences in phenotype observed in Gjirl - mice when compared to 
humans with a mutation in a single allele of Gjil. 
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CHAPTER V 
GFIlB INTERFERES WITH POSITIVE SELECTION OF TCR TRANSGENIC 
THYMOCYTES 
Introduction. 
A central tenet ofT cell-mediated immunological functions is the requirement for 
recognition of haplotype-specific MHC molecules by the TCR. Indeed, it is the 
combination of antigen and the haplotype of the presenting MHC molecule that 
determines the response or nonresponse of a mature T cell. The induction of an immune 
response requires that the TCR recognize foreign antigen in the context of self-MHC. On 
the other hand, the presentation of self antigen by self-MHC results in low-level TCR 
signaling and survival, but not activation, of T cells. This principle also governs the 
positive selection of thymocytes. Thymic antigen presenting cells present a wide variety 
of self antigen in the context of self-haplotype specific MHC molecules. In fact, it is 
thought that thymic APC have access to virtually all potential self-antigens, thereby 
providing to developing T cells the potential to interact with these self antigens. These 
interactions ensure both the development of a very diverse T cell repertoire and the clonal 
deletion of all potentially self-reactive T cells (recently reviewed in (80)). Furthermore, 
under normal physiological circumstances, thymocytes are restricted and selected by self-
MHC only, ensuring the recognition of foreign MHC as foreign. Therefore, the MHC 
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haplotype that can successfully select a T cell bearing a specific TCR is fixed and can be 
experimentally determined. 
This central principle has been exploited by researchers to generate tools that 
further enhance our understanding of TCR-MHC interactions. TCR transgenic mice have 
been generated in which T cells predominantly express only the engineered transgenic 
TCR. Both the MHC specificity and the antigenic specificity of these transgenic TCRs 
are known, allowing researchers to more closely examine TCR-antigen-MHC interaction 
as well as specific processes of T lymphopoiesis that are governed by these interactions, 
such as positive and negative selection. We have used these systems to further 
investigate the phenotype of our GFIlB transgenic mice. 
Our initial phenotypic analysis of GFIlB transgenic thymi presented results that 
were unexpected in the context of accepted theories of thymocyte selection and 
maturation. Specifically, we found that GFIlB transgenic thymocytes and T cells are 
defective in TCR signaling (Chapter 2). Currently accepted theory ofT lymphopoiesis 
suggests that a stronger or more persistent TCR signal is required for the formation of 
CD4 SP cells and that a weaker or less persistent signal results in the formation of CD8 
SP cells (recently reviewed in (81;82)). According to this theory, GFIlB transgenic mice 
should generate more CD8s and fewer CD4s when compared to wild type mice. 
Contrary to this, we discovered that GFIlB transgenic mice have an unusually high 
percentage and number of CD4 SP cells (Figure 10, chapter 2). Furthermore, these CD4 
SP cells are phenotypically mature as determined by low expression of the maturation 
marker CD24IHSA. Given the down-modulation ofTCR signals observed in GFIlB-
transgenic T cells, we reasoned that the abnormal CD4 SP cells in GFIlB transgenic mice 
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may be the result of aberrant positive selection ofDP thymocytes that should have 
received a stronger signal and, therefore, should have been deleted. 
Preliminary studies examining negative selection indicated little or no effect of 
the GFIlB transgene. These studies include flow cytometric apoptosis assays of 
thymocytes, examination of deletion of specific V~ subsets in thymocyte populations, 
and expansion and survival ofV~ subsets in the periphery (data not shown). Because no 
difference was observed between GFIlB transgenic mice and wild type littermate 
controls in these experiments, we did not further investigate negative selection as a 
mechanistic explanation for the GFIlB transgenic phenotype. Rather, we decided to 
pursue positive selection as the mechanism. 
To determine whether GFIlB affects positive selection, we crossed GFIlB 
transgenic mice with mice that express a transgenic TCR. All mice were crossed onto a 
Rag2-1- background so that no rearrangement of endogenous TCR loci would occur. In 
addition, to reduce the possibility of TCR transgene-specific effects, we used two 
different TCR transgenic lines, AND and DO.II. Both TCR transgenes are MHC Class 
II restricted and, when on a genetic background expressing the proper selecting MHC 
molecules, result in the positive selection of large numbers of CD4 SP cells (83-86). 
We discovered that in these systems, transgenic expression of GFIl B results in a 
reduction in the number of CD4 SP cells, with a concomitant increase in the number of 
DP thymocytes. Furthermore, a large percentage of those CD4 SP cells that are 
generated are phenotypically abnormal, displaying properties of both mature and 
immature SP thymocytes. In addition, micro array analysis provides insight into changes 
in the transcription levels of genes that are known to contribute to T cell activation, and 
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EMSA analysis provides preliminary evidence that these TCR signaling pathways are 
affected in GFIIB transgenic thymocytes. 
Materials and methods. 
Mice. Rag-I- TCR transgenic mice were obtained from Taconic Farms. These mice have 
bred true for generations and therefore transmit one copy of the trans gene to all progeny. 
Rag-I- GFIlB transgenic mice were generated by crossing Rag-I- mice (Taconic Farms) 
with GFIlB transgenics, all on a B6 background. GFIlB transgenic, Rag+l- progeny were 
backcrossed to Rag-I- mice to generate Rag-I- GFIlB transgenic mice. These were mated 
with Rag-I- TCR transgenics to generate litters of Rag-I- TCR transgene+ and GFIlB+ or 
GFIlB- animals for experiments. 
Flow cytometry and antibodies. Flow cytometric methods have been described in 
Chapter 3. Antibodies used include CD4 (RM4-5 and GK1.5) and CD8a (53-6.7), 
CD24a-(M1I69), CD69 (H1.2F3), and CD62L (MEL-14), all from BD Pharmingen. 
RNA isolation and microarray. For microarray analysis, single cell suspensions of 
thymocytes were prepared. Phenotypes of mice were confirmed by flow cytometric 
analysis, and RNA was extracted from thymocytes with UltraSpec RNA Isolation System 
(Biotecx) following the manufacturer's protocol. Microarray analysis was performed in 
the Brown Cancer Center Microarray core facility of the University of Louisville. 
EM SA. Electrophoretic mobility shift assays were performed according to the protocol 
described in chapter 2 with the following modifications. Probes were oligonucleotides 
from Santa Cruz Biotechnology (sc-2501, sc-2505, and sc-2525) and were labeled with 
Polynucleotide Kinase (New England Biolabs) following a standard protocol. 2.5 ~g of 
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nuclear extract was incubated with 1 uL of radio labeled oligonucleotide probe (100,000 
cpm). Complexes were electrophoresed through 6% polyacrylamide gels, dried, and 
exposed to film. 
Results and discussion. 
Transgenic expression of GFIlB results in decreased positive selection and the 
presence of abnormal MHC Class II restricted TCR transgenic thymocytes. 
To determine the effect oftransgenic expression ofGFIlB on positive selection of 
thymocytes, we crossed AND transgenic mice to GFIlB transgenic mice. The resulting 
FI progeny are H_2b/d, which is a positively selecting background for AND TCR 
transgenic thymocytes (83). When we examined the thymi of these progeny, we 
observed a large percentage ofthymocytes were CD4 SP in the GFIlB- AND transgenic 
mice, in accordance with previously published results. However, when transgenic GFIlB 
is expressed, the percentage and number of CD4 SP thymocytes is decreased to 
approximately half those of controls (Figure 24A). The total number ofthymocytes is 
not different between GFIlB transgenics and GFIlB-littermate controls, and the 
difference in the number of CD4 SP cells is inversely correlated with a difference in the 
number ofDP cells. Similar results were obtained with DO.lI/GFIlB bi-transgenics 
(Figure24B), though both the decrease in CD4 SP cells and the increase in DP cells in 
GFIlB transgenics are even more pronounced in this case. DO.lI mice do not produce 
the same large percentage ofCD4 SP cells observed in AND transgenics (86), and our FI 
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Figure 24. Transgenic GFIlB decreases the number of CD4 SP cells in Class II 
restricted TCR transgenic mice. A. Flow cytometric plot ofCD4 v CD8 of Rag-1-
AND TCR transgenic and Rag-I- AND TCR GFIlB bi-transgenic mice. DP and CD4 SP 
populations are gated, and percentage of total cells indicated. The MHC haplotypes of 
these FI mice are bid. The table below the graphs gives absolute numbers of cell 





Rag-!- AND Rag-I - AND GPIlB 
53_5% 29 _7% 
R •• -- AND (_) Rna'- AND GFIIH (,.-5) 
Cel l population 1fT cells S.D. 10 cells S.D. 
Total thymocvtcs S I.21 6.009 47.S9 9.229 
DP 15.41 3.593 24.54 smo 
CD4 SP 2S.43 2.6S0 11.80 2.S20 
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CD4SP 19.21 1.604 4.660 0.3221 
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mice are of a mixed haplotype; d (positively selecting) and b (negatively selecting). 
Therefore, we cannot rule out a role for negative selection in the disparity of CD4 SP in 
DO.Il1GFIlB bi-transgenics, though preliminary data would suggest that GFIlB does 
not affect negative selection (discussed above). Nonetheless, the results from both Class 
II restricted transgenic TCR systems are consistent with an interference of positive 
selection by transgenic GFIl B. 
Because we had observed abnormal phenotypically mature CD4 SP cells in 
GFIlB single transgenic mice (Chapter 2 and Figure 25), we examined the CD4 SP cells 
in our bi-transgenic system for the expression of several maturation markers. As normal 
thymocytes mature, they downregulate the expression of CD24 and CD69 (Figure 25). 
However, GFIlB transgenic mice display an abnormal population ofCD4 SP thymocytes 
that are CD69hi CD24lo (Figure 25). Additionally, normal thymocytes upregulate the 
expression of CD62L as they mature (data not shown). When considered together, these 
three markers can be used to track the maturation of thymocytes. The most mature 
thymocytes are those that express low levels of CD24 and CD69 and high levels of 
CD62L. These thymocytes are equivalent to immature T cells, and exit the thymus to 
take up residence in peripheral lymphoid compartments (87). 
CD62L is a homing molecule for mature T cells that directs them into the 
peripheral lymphoid compartments (88). The activities of CD24 and CD69 have not been 
firmly established in T lymphopoiesis; however, it has been suggested that CD69, a 
glycoprotein, serves as an anatomical anchor, preventing the premature egress of 
developing thymocytes (89;90). Therefore, in order to exit the thymus and home to 
peripheral lymphoid compartments, a cell must both downregulate CD69 and upregulate 
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Figure 25. GFIlB transgenic CD4 SP thymocytes display abnormal levels of 
maturation markers. Shown are plots of CD4 SP cells from one wild type and one 
GFIlB transgenic mouse. The GFIlB transgenics have an abnormal population of cells 
expressing low levels ofCD24, most of which express high levels ofCD69. In addition, 








CD62L. The increase in CD4 SP cells that we observed in our GFIl B transgenic mice 
was comprised of cells that express low levels of CD24 (Figure 1 DC), suggesting that 
these cells were phenotypically mature. However, these cells also express high levels of 
CD69 (data not shown), suggesting abnormal maturation. We therefore examined the 
CD4 SP cells generated in our GFIlB/TCR bi-transgenic systems for maturity based on 
CD24, CD69, and CD62L expression. 
As shown in Figure 26, GFIlB- TCR transgenic CD4 SP cells are mostly CD24hi 
CD69hi, with a relatively abundant population expressing intermediate levels of both 
markers, suggesting a normal maturation process. Furthermore, a good percentage of 
these cells express CD62L, suggesting phenotypically mature thymocytes with the 
capacity to exit the thymus and home to the periphery. In contrast, GFIlB+ TCR 
transgenic CD4 SP cells are largely CD2410 CD69hi, suggesting abnormal maturation. In 
addition, very few GFIlB transgenic CD4 SP cells express CD62L. Therefore, though 
GFIlB transgenic mice generate CD4 SP cells with certain markers of mature 
thymocytes, these cells may be unable to exit to the periphery and home to lymphoid 
compartments due to continued expression of CD69 and a lack of expression of CD62L, 
respectively. 
Microarray analysis reveals alterations in expression of several genes involved in 
TCR signaling pathways in GFIlB transgenic thymocytes. 
We hypothesize that GFIlB interferes with TCR-induced signaling, resulting in a 
decrease in the strength of signal that the cell interprets. Much is known about the 
pathways involved in, and the ultimate downstream effectors of, TCR-induced signals. 
Figure 27 is a simplified schematic representation of some of the major players in three 
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Figure 26. CD4 SP cells ofTCR GFIlB bi-transgenic mice do not mature normally. 
A. CD69 or CD62L v CD24 in CD4 SP thymocytes of Rag ,I, AND TCR transgenic or 
GFIlB littermates. Percentages of gated populations are indicated. B. The same 
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Figure 27. Schematic representation of major effectors in TCR signaling pathways. 
Modified from Singer and Koretzky, STKE website. The three major pathways depicted 
result in the transcriptional activation of three different factors. Activation of both NF-
KB and AP-l requires signaling through the second messenger diacylglycerol (DAG). 
However, the activation ofNF-KB is PKC-dependent whereas the activation of AP-l is 
mediated through the Ras pathway. Activation ofN-FAT is mediated through the 
calcium! calcineurin pathway. 





distinct TCR signaling pathways. Each pathway activates a distinct downstream effector. 
That is, calciumlcalcineurin-mediated signaling results in the activation of Nuclear Factor 
of Activate T-cells (N-FAT), whereas PKC-dependent signaling results in an increase in 
the transcriptional activation of Nuclear Factor kappa B (NFKB), and signaling through 
the Ras pathway induces activation of AP-l, the Fos/Jun family of transcriptional 
activators. As all of these are required for a full response to TCR activation, interference 
with any of them would result in a decrease in that response. We therefore performed 
micro array analysis on TCRIGFIlB bi-transgenic thymi and examined the expression of 
known members of these pathways. 
Figure 28 is a table of absolute signals from our microarray analysis. Included in 
the table are genes involved in TCR signaling that we found to be different between 
GFIlB+ and GFIlB- mice. We first examined the expression of Gfil, which we have 
shown to be repressed by GFIlB, and of GfilB itself, as we would expect to see increased 
levels of Gfil B transcript in GFIlB transgenic cells. Indeed, GFIlB transgenic 
thymocytes express drastically reduced levels of Gfil message and increased levels of 
GfilB transcript when compared to littermate controls (Figure 28). Furthermore, GFIlB 
transgenics express increased levels of diacylglycerol kinase zeta (DGKt;), a negative 
regulator of diacylglycerol (DAG) signaling. As depicted in Figure 27, this increase 
alone may be sufficient to decrease the activation of both NFKB and AP-l upon induction 
ofTCR signals. Additionally, GFIlB transgenics express decreased levels of both PKC8 
and RasGRP2, further contributing to the block in activation ofNFKB and AP-l, 
respectively. These results must be confirmed by either Northern blot analysis or RT-
peR. However, in order to justify further investigation into this potential mechanism, we 
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Figure 28. GFIlB transgenic thymocytes display abnormal expression of 
transcripts relevant to TCR signaling pathways. Signals of Affymetrix MOE430 
microarray of RNA in thymocytes from two GFIlB/AND bi-transgenic and two GFIlB-
AND TCR transgenic littermate controls. In GFIlB transgenic animals, Gfil transcript is 
reduced, and GfilB transcript is increased, when compared to GFIlB-littermate controls. 
The array has two different probe sets to examine DGK(; both are listed. Though 
absolute values for GFIlB transgenic animals are not always higher than controls, the 
trend is that GFIlB transgenic thymocytes have increased levels of DGK(message. The 
signal for P KC() is lower in the single probe set for that gene, and all three probe sets for 
RasGRP2 show decreased levels of this transcript in the GFIlB transgenics. Signal 
values were normalized using global scaling to a constant factor to compensate for 
variation in sample processing. 
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Figure 28 
ANDTg + + + + 
GFIlB Tg - - + + 
Gfi1 288.8 367.4 61.5 13.0 
Gfi1B 9.5 7.8 904.5 1036.9 
DGK zeta 2312.9 3067.9 3979.9 3059.6 
DGK zeta 299.6 521.5 834.5 742.3 
PKC theta 796.5 706.8 369.6 455.2 
RasGRP2 127.1 168.3 93.3 93.0 
RasGRP2 116.2 152.5 102.1 83.5 
RasGRP2 96.8 79.8 57.6 66.1 
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needed preliminary evidence that the downstream effectors of these signaling pathways 
are also affected in the GFIlB transgenics. 
EMSA analysis suggests that NFKB and AP-l are less active in GFIlB transgenic 
thymocytes. 
NFKB and AP-I are activated in response to TCR signals, and this activation is 
often measured by examination of DNA-binding capacity of these factors in nuclear 
extracts. We therefore performed EMSA analysis to compare the activity of these 
transcription factors in GFIlB transgenic thymocytes and GFIlB negative littermate 
controls. As a control for equal nuclear extract loading, we included probes for CIEBP, 
which is not responsive to TCR activation. Figure 29 shows the results of this analysis 
for both AND and DO.II TCR transgenics. In AND TCR transgenics, expression of 
transgenic GFIlB results in a decrease in DNA binding by both NFKB and AP-I, but 
does not affect DNA binding by CIEBP (Panel A). These results are consistent with the 
gene array data in which we observed increased expression of Dgk( and decreased 
expression of both PKC8 and RasGRP2e (Figure 28). Examination of the DNA binding 
activity of these same transcription factors from DO.lI GFIlB transgenic thymocytes 
revealed decreased activity ofNFKB, but not of AP-I or CIEBP. These preliminary 
results, while far from conclusive, provide biological impetus to continue exploring the 
effects ofGFIlB on both PKC- and Ras-mediated TCR signaling. 
Future experiments to determine whether these pathways are affected in the 
GFIlB-mediated block to positive selection include Northern blot or RT-PCR analysis as 
previously mentioned. In addition, promoter and ChiP analyses would help to determine 
whether the decreased expression of PKC8 and RasGRP2 are the result of direct 
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Figure 29. Transgenic GFIlB decreases DNA binding by TCR downstream 
effectors in bulk thymocytes. A. EMS A analysis of DNA binding by NFrl3, AP-I, and 
CIEBP in thymocyte nuclear extract from Rag-I- AND TCR GFIlB bi-transgenic and 
littermate controls. Transgenic GFIlB results in decreased intensities of shifts for both 
NFrl3 and AP-I, but not for C/EBP. B. The same analyses applied to nuclear extract 
from a different transgenic TCR (Rag -I-DO .11 TCR transgenic mice) reveals decreased 
binding by NFrl3, but not by AP-I or CIEBP. 
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Figure 29 
A Rag-/- AND TCR transgenic 
GFIlB tg - + + + + + + 
B Rag-/- DOll TCR transgenic 
GFI1B tg - + + + 
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repression by GFIlB. Expanding on the results obtained by EMSA, the same analyses 
should be repeated on sorted DP TCRhi thymocytes (the stage at which positive selection 
occurs and endogenous GfilB is expressed) to detennine whether in this population, the 
activities ofNFKB and AP-l are truly decreased. Additionally, TCR transgenic 
thymocytes could be activated and the same analyses perfonned to further support the 
theory that this is a TCR-mediated inducible effect. In sum, the data presented here are 
preliminary and provide a solid framework and good starting point for future work 




The T lymphopoietic process is of great interest for many reasons. Not only has 
the study of this developmental pathway led to a greater understanding of immunity and 
autoimmunity, but it is also a good model for studying developmental processes in 
general. While most development ceases after embryogenesis, T lymphopoiesis 
continues into adulthood, albeit at a slower rate. Furthermore, and perhaps most pertinent 
in the context of these studies, there is a close relationship between development and 
oncogenesis. That is, many of the factors that regulate development also drive the 
oncogenic process (recent reviews include (91-94)). 
The transcriptional repressors GFIl and GFIlB have been identified as oncogenes 
and perform defined oncogenic functions. Indeed, these factors were originally identified 
in Moloney Murine Leukemia Virus-induced leukemia systems, and were characterized 
as being able to block growth arrest, differentiation, and apoptosis (8-10;31 ;62;76). 
Sequence analysis of Gfil and Gfil B revealed extensive homology in both the N-terminal 
region, which encodes the transcriptional repressor SNAG domain, and in the C-terminal 
region encoding six Cis-His Zn fingers (Figure 3) (10). Furthermore, in vitro assays 
revealed that GFIl and GFIlB bind to nearly identical recognition sequences and repress 
transcription in a SNAG-dependent manner (9;10;15). However, Gfil and GfilB showed 
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tissue-specific expression patterns (10), leaving an apparent dichotomy; if these two 
factors are biochemically and functionally redundant, why are there two differentially 
expressed proteins? 
This work was initiated to address the question of functional redundancy between 
GFIl and GFIlB. We chose to examine the effects of transgenic expression ofGFIl or 
GFIlB in T cells because GFIl had already been shown to have a biological function in 
these cells. During the course of our work, other literature has also emerged examining 
the effects of either transgenic expression of GFIl or deficiency of either Gfil or Gfil B. 
What has emerged from the work done to date is a story of two unique factors, each 
having distinct roles in development. Gfil is essential for normal T lymphopoiesis and 
granulopoiesis, while GfilB is required for definitive erythropoiesis (11;16-18). The 
published findings of the studies producing these data have been mentioned in more 
detail throughout the earlier chapters of this dissertation, and will not be discussed further 
here. Instead, this chapter will focus on the distinct roles ofGFIl and GFIlB in positive 
selection of developing thymocytes, drawing both from a body of published literature and 
from the data generated in this lab and presented in this dissertation. 
Based on early biochemical studies, we began this work with the hypothesis that, 
if expressed independently in the same tissue and in the same manner, GFIl and GFIlB 
may perform redundant functions. To test this hypothesis, mice were generated to 
express transgenic GFIl or GFIlB in developing and mature T cells. One of our first 
observations of GFIl transgenic T cells is that they respond more robustly to activation 
through the TCR (Figure 8), a result that has been corroborated by others (21). On the 
contrary, the same analysis applied to GFIlB transgenic T cells yielded a directly 
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opposite result. That is, GFIlB-transgenic T cells are defective in activation (Figure 8). 
This was perhaps surprising at first, given the biochemical similarities of GFIl and 
GFIlB. However, the opposing functions of these two factors in T cells may have been 
suggested by very early studies in which GFIlB was found to be up-regulated in 
Moloney Murine Leukemia Virus (MoMuL V)-induced B cell tumors, but not in tumors 
of T cell origin (10). Since T cells require TCR signals to survive, the lack of GFIl B in 
these tumors may have been a clue to the detrimental effect ofGFIlB on TCR-mediated 
activation. 
Our data suggest that GFI 1 B negatively affects normal positive selection of 
thymocytes by interrupting TCR signaling events. GFIl is required for normal T 
lymphopoiesis (11; 16). Thymi of our GFIl and GFIl B transgenic mice have different 
phenotypes. Our GFIl transgenic system failed to reproduce the phenotype observed in 
an earlier publication (36), a result that will be discussed in more detail below. However, 
our GFIlB transgenics displayed abnormal thymocyte development, manifested by an 
increase in the CD4/CD8 ratio and a decrease in the expression of the late activation 
marker IL 7Ra. Furthermore, in two independent mouse models that express specific 
MHC Class II restricted TCRs, the expression of transgenic GFIIB resulted in a decrease 
in the number ofCD4 SP cells. This result suggests that overexpression ofGFIlB 
interferes with positive selection of DP thymocytes. In addition, our data show that 
Gfil B is up-regulated in thymocytes that are undergoing positive selection events. 
Considered together with the GFIlliterature and the effects ofGFIl and GFIlB on T cell 
activation, our data implicate GFIl and GFIlB in TCR signaling. 
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I propose a model ofT lymphopoiesis in which GFIl enhances, while GFIlB 
opposes, positive selection. I propose that these opposite effects are engendered by at 
least two mechanisms. One mechanism is the distinct activities ofGFIl and GFIlB that 
result from their unique intervening sequences. The other mechanism is direct repression 
of GjiJ by GFIlB at the DP stage during which TCR signaling must be fine-tuned in 
order for proper selection to occur. (See Figure 30.) Furthermore, I propose that these 
effects can be observed at earlier stages of thymocyte development, a concept that will be 
expanded below. 
Evidence for the stimulatory effect of GFIl on positive selection comes from the 
study of GFIl transgenic mice. First, as mentioned throughout this dissertation as a 
fundamental finding, GFIl transgenic T cells are more responsive to TCR stimulation 
than are wild type T cells. TCR signaling is required for positive selection. This 
requirement raises the possibility that enhanced signaling may result in enhanced 
selection. Conversely, because an overly strong signal results in negative selection, it 
remains possible that by enhancing TCR signaling, GFIl could actually increase negative 
selection as opposed to positive selection, resulting in an overall decrease in the 
production of SP thymocytes. However, in one published report, GFIl transgenic thymi, 
though drastically reduced in overall cell number, showed an increase in the percentage 
of SP thymocytes and a decrease in the percentage of DP thymocytes when compared to 
littermate controls (36). This increase occurred with no consistent bias toward either the 
CD4 or CD8 lineage. A simple precursor-progeny ratio, then, would suggest that GFIl 
does indeed enhance the positive selection of DP thymocytes. 
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Evidence for the deleterious effect ofGFIlB on positive selection has been 
presented in chapters 3 and 5 of this dissertation. Our data show that in isolation, 
transgenic expression ofGFIlB results in an abnonnally matured population ofCD4 SP 
cells and a decrease in the number of CD8 SP cells that are generated. The lack of CD8 
SP cells in GFIIB transgenic mice suggested defective positive selection, but was made 
less precise in light of the increased numbers ofCD4 SP cells. However, we 
hypothesized that the increased number ofCD4 SP cells in the GFIlB transgenics is itself 
the result of decreased TCR signals. This aberrant signaling leads to the positive 
selection of cells that should have been eliminated. These abnonnal cells are then unable 
to develop further into functional immune cells and exit the thymus. Indeed, in the 
restricted selecting environment engendered by expression of a Class II-restricted 
transgenic TCR, transgenic GFIlB decreases the number ofCD4 SP cells that are 
generated, with a concomitant increase in the DP population. Again, precursor-progeny 
relationship would suggest a defect in positive selection. Therefore, it seems logical that, 
due to a lack of proper TCR and/or IL7 signaling, GFIlB transgenic thymocytes are at a 
disadvantage for survival. 
The decrease in CD8 SP cells observed in GFIlB single transgenic mice has been 
tied both to decreased expression ofIL7Ru and to a lack ofGFIl expression. The partial 
restoration of this population by forced expression of GFIl not only emphasizes the 
effects of GFIl B-mediated repression of Gfil, but also places GFIl uniquely in the path 
of CD8 SP development and further supports a role for GFIl in survival and positive 
selection. Furthennore, these data highlight the distinct roles ofGFIl and GFIlB in 
thymocyte development. The most straightforward explanation for the results is that 
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Figure 30. Schematic representation of GFIl and GFIlB in positive selection of DP 
thymocytes. A. The effect of overexpression of GFIl. Too much GFIl results in 
increased positive selection and an imbalance of SP to DP cells, in the direction of SP. 
The region between the SNAG domain and the Zn fingers is encircled and is likely to 
mediate this GFIl-specific effect. B. The effect of overexpression ofGFIlB. Too much 
GFIlB results decreased positive selection and an imbalance of SP to DP cells in the 
direction ofDP. Both SNAG-dependent complete repression ofGfil and SNAG-
independent GFIlB-specific functions contribute to this effect. The unique region of 
GFIlB is encircled. C. GFIl and GFIlB in normal positive selection. Moderate 
expression ofGFIlB results in moderate repression ofGfil and proper levels ofGFIl 
protein. Thus, both factors are present to contribute unique functions and maintain 
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the unique region of GFIl is responsible for supplying the survival signal necessary for 
CD8 SP fonnation, which GFIIB is unable to provide. It is interesting to consider that 
GFIl has been shown to physically interact with Protein Inhibitor of Activated STAT 
(PIAS)3, an inhibitor of Signal Transducer of Activated T cells (STAT)3, through this 
unique region. STAT3 has been shown to transduce signals through both IL2 and IL6 
pathways in T cells, although a function for STAT3 in T lymphopoiesis has not been 
defined. The interaction of GFIl with PIAS3, and possible implications thereof, are 
discussed in further detail below. However, though strictly correlative, these data suggest 
a role for GFIl-mediated ST AT3 activation in the generation and selection of CD8 SP 
thymocytes. 
The most novel data presented in this dissertation are those that predict a role for 
GFIlB in nonnal T lymphopoiesis. In addition to the evidence gleaned from transgenic 
mouse models, we and our collaborators have provided the first evidence that GFIlB is 
expressed in nonnal developing thymocytes (Figure 6). This physiological expression of 
GjilB at stages of positive selection provides insight into the function ofGFIlB in T 
cells. Furthennore, our data showing repression of Gjil by GFIlB begins to elucidate a 
partial mechanism for the action of GFIIB in T cells; to specifically repress the 
transcription of the gene encoding the signal-enhancing factor GFII, thereby providing a 
damper of TCR signaling in cells poised to differentiate into the SP stage. However, I do 
not suggest that all of the functions of GFIl B are dependent upon its repression of Gjil. 
Indeed, we have provided evidence to the contrary in that transgenic GFIl does not 
correct all of the phenotypes engendered by transgenic expression ofGFIlB. However, it 
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remains possible that the inability of transgenic GFIl to reverse all phenotypes of 
transgenic GFIlB is a result of inadequate expression of the transgene. 
At least two other possible mechanisms could contribute to GFIlB's function in T 
cells. The first is direct competition with GFIl for specific target genes that are 
differentially regulated by GFIl and GFIlB. The other is unique GFIlB-specific 
interaction with other proteins that have functions in signal transduction. In fact, though 
distinct in execution, each of these proposed mechanisms is dictated by the unique non-
homologous central regions ofGFIl and GFIlB. 
The first proposed molecular mechanism ofGFIlB antagonism ofGFIl function 
in T cells is the direct competition ofGFIl and GFIlB for binding to target genes. For 
antagonistic functions to result from one or the other factor binding preferentially to 
target genes, the genes in question must be differentially regulated by GFIl and GFIlB. 
This differential regulation must be mediated by the non-SNAG or Zn finger regions of 
the two proteins. These non-homologous regions may provide different protein-protein 
interaction domains that would interact with different transcription factors or co-repressor 
(or co-activator) proteins, thereby providing the basis for differential regulation. These 
interactions could in fact influence the DNA binding ofGFIl and GFIlB, or the distinct 
nature of the interactions may change the context of transcriptional control after DNA 
binding. Either mechanism could result in opposing outcomes dependent on the presence 
of either GFIl or GFIl B. 
Interaction with different binding partners could alter the DNA binding 
specificities of GFIl and GFIlB. It can be assumed that these two factors normally exist 
in a complex with other proteins, which would bind to DNA as a unit. Our EMSA data 
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would suggest that this is true for GFIl (Figure 21). In this proposed mechanism, the 
components necessary for interaction are complexed together before being recruited to 
DNA. Therefore, ifGFIl and GFIlB are part of pre-existing complexes before binding 
to DNA, the presence of the interacting partners could alter the DNA binding of GFIl 
and GFIlB in at least two ways. If the interacting partner is itself a transcription factor 
with a distinct DNA recognition sequence, it is likely to change the affinity of GFIl or 
GFIlB binding by itself making contact with the DNA in the presence of its recognition 
element. This interaction would in turn stabilize the overall protein-DNA interaction and 
increase the apparent affinity ofGFIl or GFIlB for its binding site. Alternatively, the 
GFIl- or GFIlB-interacting proteins present in the pre-formed nuclear complex may not 
bind to DNA at all. Rather, they could impose a slight conformational change in GFIl or 
GFIlB, thereby slightly altering the affinity for binding. The non-homologous nature of 
the intervening sequences ofGFIl and GFIlB suggest distinct protein-protein 
interactions and unique binding partners. Therefore, the mechanisms discussed above 
would confer differential regulation of target genes in at least two ways. First, binding 
affinities ofGFIl and GFIlB for specific sites would be different. Second, the unique 
complexes would likely provide distinct regulation of the target genes. 
Another model to consider is transcriptional regulation in the context of a 
repressosome. Repressosomes and enhanceosomes are nucleoprotein complexes that 
assemble on regulatory regions of DNA to regulate the transcription of genes (recently 
reviewed in (95-97)). The success of a repressosome depends on the DNA recognition 
sequences of specific transcription factors and on the presence of the factors themselves. 
Furthermore, proper binding of the DNA-interacting factors specifies the conformation 
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for the recruitment of specific co-repressors. When all components are present, the 
repressosome is assembled into a three dimensional structure that often involves bending 
of DNA to bring transcription factors into close proximity to one another, allowing 
necessary protein-protein interactions. Therefore, in this very complex system, the 
composition of molecular species is very tightly controlled. That is, incorporation of a 
non-functional factor, or perhaps the wrong factor, would result in interruption of the 
protein-protein interactions that ensure proper repressosome formation and subsequent 
transcriptional regulation by the repressosome complex. The intervening sequences of 
GFIl and GFIlB are dissimilar and therefore would not be predicted to interact with 
similar proteins. Thus, if GFIl B were to bind to a recognition site that is part of a GFIl-
requiring repressosome, then the final transcriptional regulation would not be correct. 
This theory, again, depends on the non-homologous regions ofGFIl and GFIlB to confer 
the differences. However, this model is more likely to be relevant in situations where one 
or the other factor is aberrantly overexpressed, as the binding of the correct factor in the 
repressosome would stabilize the tertiary structure. This stabilization would energetically 
favor the binding of the correct factor such that this would be the prevalent composition 
unless enough of the incorrect factor was present to shift the equilibrium of binding. 
The second proposed molecular mechanism is quite straightforward, and therefore 
very attractive to consider, though there is very little evidence to support it as yet. GFIl 
has been shown to confer signaling advantages to cells by increasing the activity of 
Signal Transducer of Activated T cells (STAT)3. GFIl does this by interacting with, and 
interrupting the function of, Protein Inhibitor of Activated STAT (PIAS)3 (20). PIAS3 
inhibits the DNA binding capability of activated STAT3 by binding to and sequestering 
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the active STAT3 dimer (98). However, PIAS3 has also been shown to have other 
effects in the cell, including mediation of sumoylation through interaction with SUMO-l 
(99; 1 00). SUMO is a small molecule that resembles ubiquitin and is conjugated to 
proteins in a process similar to ubiquitination. However, sumoylation often occurs on 
transcription factors in the nucleus, and does not lead to proteasomal degradation. 
Rather, sumoylation regulates the subnuclear localization and activity of the target 
transcription factors (101). Therefore, GFIl-PIAS3 interaction may signify alterations in 
GFIl's transcriptional activity in addition to interference with STAT3 activity. 
The interaction of GFIl with PIAS3 has been mapped to the region between the 
SNAG domain and the Zn fingers (20), which shares no homology with the same region 
ofGFIlB. Therefore, the unique region ofGFIl can act to sequester signaling proteins 
and change the context of signaling pathways independent of any direct transcriptional 
repression. It is interesting to consider that PIAS3 is likely only one of several proteins 
with which GFIl can interact, and that GFIl B, due to having no homology to GFIl in 
this region, at the very least does not interact with the same signal-enhancing proteins as 
does GFIl and may indeed interact with different proteins to confer opposite effects on 
signal transduction. 
These same principles may be in place earlier in T lymphopoiesis. GFIl has been 
suggested to playa role in early thymocyte development at the stage of beta selection, 
which occurs at the DN3 stage of thymocyte development (11 ;36). Our data have shown 
that Gfil B is up-regulated at this stage of development. It is therefore possible that, 
similar to its effect on TCR signaling, GFIlB decreases pre-TCR-mediated signals to 
influence these early maturation steps. However, our GFIl transgenics did not reproduce 
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the published phenotype, nor did we observe an effect of transgenic GFIlB at this stage. 
Therefore, the roles of GFIl and GFIlB in beta selection cannot be clearly defined at this 
point. Nonetheless, there does seem to be a function for GFIl prior to beta selection, as 
determined by examination of Gfil deficient mice and corroborated by data from our 
GFIlB transgenics. 
Mice that are deficient for Gfil display a severe block to T lymphopoiesis in the 
very early DNI to DN2 transition (11). Our expression data corroborate a role for GFIl 
at this step in that we observe an approximately IO-fold increase in Gfil message levels 
in DN2 versus DNI cells (Figure 6). This increase in expression suggests a requirement 
for the presence of GFIl in this transition, and supports the result that lack of Gfil causes 
a block in early thymocyte development. Furthermore, GFIl transgenic mice have a 
larger percentage of both a/~ TCR-expressing and ,,(IS TCR-expressing cells in total 
thymocyte populations (36). While the increase in a/~ cells may be attributed to the 
previously mentioned increase in the percentage of SP thymocytes, the increased 
percentage of ,,(IS T cells should be manifested in the DN population, as ,,(IS lineage 
commitment occurs prior to expression of either CD4 or CD8. Furthermore, normal ,,(IS 
T cells do not express either co-receptor. We observed a similar result in our GFIlB 
transgenic mice. Upon examination ofDN thymocytes, we discovered a reproducible 
marked increase in the proportion of cells that express either TCR (data not shown). 
Since both overexpression models show similar results, it is interesting to contemplate 
that the effect ofGFIl and GFIlB in early T lineage commitment steps is SNAG and Zn 
finger dependent. In normal thymocytes, only Gfil is expressed at these very early 
stages, further suggesting redundancy of these two factors at this stage. Again, these data 
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are merely suggestive, and require more specific experiments to finally answer the 
question of the role of GFIl in early T lineage commitment. 
GFIl and GFIlB, in addition to being potent oncogenic factors, are important 
regulators of development. The normal physiological functions of these two proteins are 
just beginning to be understood. The dramatic abnormalities engendered by a complete, 
unconditional loss of either factor make gene-targeted mouse systems less than ideal for 
studying the subtle nuances of temporal or conditional changes in expression, such that 
are likely to be encountered in disease states. Work in the near future is likely to include 
conditional knockout systems in which loss ofGjil or GjilB can be directed to specific 
cells at specific stages of development. Such experiments in developing T lymphocytes 
would clarify some of the finer points of control that these two fascinating transcription 
factors mediate during the process of T lymphopoiesis. 
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LIST OF ABBREVIATIONS 
TCR; T cell receptor 
MHC; Major histocompatibility complex 
GFIl; Growth factor independence-I 
GFIlB; Growth factor independence-IB 
IL 7; Interleukin 7 
IL 7R; Interleukin 7 receptor 
NK; Natural killer 
RAG; Recombinase activating gene 
DN; Double negative 
DP; Double positive 
SP; Single positive 
EGRI; Early growth response-I 
NF AT; Nuclear factor of activated T cells 
NFKB; Nuclear factor kappa B 
AP-I; Activator protein 1 
BCL2; B cell lymphoma 2 
MAPK; Mitogen activated protein kinase 
IL-2; Interleukin 2 
SNAG; Snail and GFIl 
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TRAF5; TNFR -associated factor 5 
LKLF; Lung Kruppellike factor 
ID; Inhibitor of DNA binding 
ChIP; Chromatin immunoprecipitation 
sacs; Suppressor of cytokine signaling 
FACS; Fluorescence activated cell sorting 
RT-PCR; Reverse transcriptase-polymerase chain reaction 
WT; Wild type 
IRF -1; Interferon regulatory factor-1 
SEM; Standard error of the mean 
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